US20060194729A1 - Method of promoting natural bypass - Google Patents
Method of promoting natural bypass Download PDFInfo
- Publication number
- US20060194729A1 US20060194729A1 US11/359,102 US35910206A US2006194729A1 US 20060194729 A1 US20060194729 A1 US 20060194729A1 US 35910206 A US35910206 A US 35910206A US 2006194729 A1 US2006194729 A1 US 2006194729A1
- Authority
- US
- United States
- Prior art keywords
- bmp
- proteins
- growth factor
- protein
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title abstract description 47
- 230000001737 promoting effect Effects 0.000 title description 5
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 96
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 96
- 239000000203 mixture Substances 0.000 claims abstract description 71
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 38
- 230000000921 morphogenic effect Effects 0.000 claims description 15
- 239000003102 growth factor Substances 0.000 claims description 13
- 230000033115 angiogenesis Effects 0.000 claims description 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 11
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims description 7
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims description 7
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 6
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 5
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 229940029303 fibroblast growth factor-1 Drugs 0.000 claims description 5
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims description 4
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 4
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 4
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 4
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 claims description 4
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims description 4
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 claims description 3
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- 101710151715 Protein 7 Proteins 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 239000004633 polyglycolic acid Substances 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 229940072041 transforming growth factor beta 2 Drugs 0.000 claims description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 2
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 1
- 108010009583 Transforming Growth Factors Proteins 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 23
- 239000002870 angiogenesis inducing agent Substances 0.000 abstract description 17
- 230000002491 angiogenic effect Effects 0.000 abstract description 17
- 238000004128 high performance liquid chromatography Methods 0.000 abstract description 16
- 238000000108 ultra-filtration Methods 0.000 abstract description 8
- 108010074415 Angiogenic Proteins Proteins 0.000 abstract description 6
- 102000008076 Angiogenic Proteins Human genes 0.000 abstract description 6
- 238000000746 purification Methods 0.000 abstract description 5
- 238000005571 anion exchange chromatography Methods 0.000 abstract description 4
- 238000005277 cation exchange chromatography Methods 0.000 abstract description 4
- 235000018102 proteins Nutrition 0.000 description 88
- 230000017531 blood circulation Effects 0.000 description 36
- 239000000499 gel Substances 0.000 description 34
- 241001465754 Metazoa Species 0.000 description 29
- 239000007924 injection Substances 0.000 description 27
- 238000002347 injection Methods 0.000 description 27
- 238000011282 treatment Methods 0.000 description 23
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 230000000694 effects Effects 0.000 description 19
- 238000001356 surgical procedure Methods 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 16
- 239000004005 microsphere Substances 0.000 description 16
- 239000008280 blood Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000001802 infusion Methods 0.000 description 11
- 230000000302 ischemic effect Effects 0.000 description 11
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 10
- 210000004204 blood vessel Anatomy 0.000 description 10
- 101150100117 gfm1 gene Proteins 0.000 description 10
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 9
- 238000002583 angiography Methods 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 229960001089 dobutamine Drugs 0.000 description 9
- 230000033001 locomotion Effects 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 210000001367 artery Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000000284 resting effect Effects 0.000 description 8
- 230000006444 vascular growth Effects 0.000 description 8
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 7
- 102100027935 Attractin-like protein 1 Human genes 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 238000002592 echocardiography Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 208000028867 ischemia Diseases 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 5
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 5
- 241000282465 Canis Species 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 5
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 5
- 241000286209 Phasianidae Species 0.000 description 5
- 229960005305 adenosine Drugs 0.000 description 5
- -1 aliphatic amino acids Chemical class 0.000 description 5
- 108010016628 ameroid Proteins 0.000 description 5
- 210000004351 coronary vessel Anatomy 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 229940069328 povidone Drugs 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 102000002278 Ribosomal Proteins Human genes 0.000 description 4
- 108010000605 Ribosomal Proteins Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 229950004398 broxuridine Drugs 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 230000000304 vasodilatating effect Effects 0.000 description 4
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical group CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 3
- 102000013563 Acid Phosphatase Human genes 0.000 description 3
- 108010051457 Acid Phosphatase Proteins 0.000 description 3
- 206010002329 Aneurysm Diseases 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 102000016943 Muramidase Human genes 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 238000005349 anion exchange Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000005341 cation exchange Methods 0.000 description 3
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 210000001105 femoral artery Anatomy 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 230000002962 histologic effect Effects 0.000 description 3
- 230000003601 intercostal effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000036262 stenosis Effects 0.000 description 3
- 208000037804 stenosis Diseases 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000334119 Coturnix japonica Species 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 102100039869 Histone H2B type F-S Human genes 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 102000005937 Tropomyosin Human genes 0.000 description 2
- 108010030743 Tropomyosin Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000006427 angiogenic response Effects 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000002586 coronary angiography Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000003398 denaturant Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 230000010016 myocardial function Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004895 regional blood flow Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 2
- 230000007998 vessel formation Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010090665 Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase Proteins 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 102000009890 Osteonectin Human genes 0.000 description 1
- 108010077077 Osteonectin Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010065084 Phosphorylase a Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 239000004792 Prolene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 1
- 229960004359 iodixanol Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 238000011542 limb amputation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940106885 marcaine Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- YPJUNDFVDDCYIH-UHFFFAOYSA-N perfluorobutyric acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)F YPJUNDFVDDCYIH-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to a method for inducing the growth of blood vessels in instances where it is desirable to increase the supply of blood to a portion of a living body. More particularly, the present invention comprises a novel angiogenic factor. Still more particularly, the present invention relates to the use of mixtures of protein extracted from bone to cause a natural vascular bypass effect.
- Atherosclerosis affects the blood vessels, including those of the heart, and is a major cause of cardiovascular disease, stroke and peripheral vascular disease.
- This disease may have its beginnings early in life and is first noted as a thickening of the arterial walls. This thickening is an accumulation of fat, fibrin, cellular debris and calcium.
- the resultant narrowing of the lumen of the afflicted vessel is called stenosis.
- Stenosis impedes and reduces blood flow.
- Hypertension and dysfunction of the organ or area of the body that suffers the impaired blood flow can result.
- the vessel wall loses the ability to expand and contract.
- the vessel loses its viability and becomes weakened and susceptible to bulging, also known as aneurysm. In the presence of hypertension or elevated blood pressure, aneurysms will frequently dissect and ultimately rupture.
- Small vessels such as the arteries that supply blood to the heart, legs, intestines and other areas of the body, are particularly susceptible to atherosclerotic narrowing.
- the resultant loss of blood supply to the leg or segment of the intestine may result in gangrene.
- Atherosclerotic narrowing of one or more of the coronary arteries limits and in some instances prevents blood flow to portions of the heart muscle.
- pain, cardiac dysfunction or death may result. Because the consequences of blocked arteries are so serious, reliable treatments are highly desirable.
- CABG coronary artery bypass grafting
- PTCA percutaneous transluminal coronary angioplasty
- TGF- ⁇ transforming growth factor beta
- PDGF platelet-derived growth factor
- bFGF basic fibroblast growth factor
- VEGF vascular endothelial growth factor
- the present invention comprises an angiogenic factor that is easily manufactured from readily available materials, easily administered by the surgeon and effective at stimulating the growth of new blood vessels into the treated tissue.
- the angiogenic factor of the present invention comprises a group of proteins extracted from bone. It has been found that the mixtures of proteins produced by certain processes are particularly effective angiogenic agents. These angiogenic agents can be administered as part of the treatment of an existing vascular disorder, or can play a role in early intervention and prevention if administered in certain cases.
- the present angiogenic agents can be introduced into tissue in the vicinity of an occluded vessel so as to cause the formation of new vessels that bypass the occluded vessel. In this manner, a natural bypass mechanism is provided.
- the angiogenic mixtures of bone proteins used according to the present invention are produced by a multi-step process that includes at least one ultrafiltration step, an anion exchange chromatography step, a cation exchange chromatography step and a high performance liquid chromatography (HPLC) purification step.
- a multi-step process that includes at least one ultrafiltration step, an anion exchange chromatography step, a cation exchange chromatography step and a high performance liquid chromatography (HPLC) purification step.
- the invention provides a method for promoting natural bypass in a mammal so provide increased blood flow to tissue served by an occluded or partly occluded vessel, a method for promoting vessel growth to heal a heart artery that has been blocked, or a method for promoting angiogenesis to assist in recovery from tissue damage.
- the method preferably comprises administering to the mammal a mixture of proteins derived from ground bone.
- the mixture of proteins preferably comprises at least two growth factors selected from the group consisting of bone morphogenic protein-2 (BMP-2), bone morphogenic protein-3 (BMP-3), bone morphogenic protein-4 (BMP-4), bone morphogenic protein-5 (BMP-5), bone morphogenic protein-6 (BMP-6), bone morphogenic protein-7 (BMP-7), transforming growth factor ⁇ 1 (TGF- ⁇ 1), transforming growth factor ⁇ 2 (TGF- ⁇ 2), transforming growth factor ⁇ 3 (TGF-p3), and fibroblast growth factor 1 (FGF-1).
- BMP-2 bone morphogenic protein-2
- BMP-3 bone morphogenic protein-3
- BMP-4 bone morphogenic protein-4
- BMP-5 bone morphogenic protein-5
- BMP-6 bone morphogenic protein-6
- BMP-7 bone morphogenic protein-7
- TGF- ⁇ 1 TGF- ⁇ 1
- TGF- ⁇ 2 transforming growth factor
- the mammal to which the present method is applied can be a human, and the mixture can be administered subcutaneously, intramuscularly, or intravenously.
- the bone-derived protein mixture may be derived from bovine bone.
- the mixture can be administered discretely or continuously.
- the mixture further comprises a growth factor selected from insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF), hepatocyte growth factor (HGF), transforming growth factor ⁇ (TGF- ⁇ ), or platelet-derived growth factor (PDGF), and optionally includes a preservative or an adjuvant.
- IGF-1 insulin-like growth factor-1
- EGF epidermal growth factor
- HGF hepatocyte growth factor
- TGF- ⁇ transforming growth factor ⁇
- PDGF platelet-derived growth factor
- Particularly preferred mixtures comprises BMP-2, BMP-3, BMP-7, TGF- ⁇ , and FGF, or the mixture derived by (i) grinding mammalian bone, to produce ground bone; (ii) cleaning the ground bone, to produce cleaned ground bone; (iii) demineralizing the cleaned ground bone, to produce demineralized cleaned ground bone; (iv) extracting protein from the demineralized cleaned ground bone using a protein denaturant; to yield extracted protein; (v) ultrafiltering the extracted protein to separate out high molecular weight proteins; (vi) ultrafiltering the extracted protein to separate out low molecular weight proteins; (vii) transferring the extracted protein to a non-ionic denaturant; (viii) subjecting the extracted protein to an anion exchange process; (ix) subjecting the extracted protein to a cation exchange process; and (x) subjecting the extracted protein to a reverse phase HPLC process.
- FIG. 1 illustrates an SDS-PAGE of one embodiment of the present angiogenic protein mixture, both in reduced and non-reduced forms
- FIG. 2 is an SDS-PAGE gel of HPLC fractions 27 - 36 of a protein mixture according to an embodiment of the present invention.
- FIG. 3 is an SDS-PAGE gel with identified bands indicated according to the legend of FIG. 4 ;
- FIG. 4 is an SDS-PAGE gel of a protein mixture according to an embodiment of the present invention with identified bands indicated, as provided in the legend;
- FIG. 5 is a two dimensional (2-D) SDS-PAGE gel of a protein mixture according to an embodiment of the present invention with internal standards indicated by arrows;
- FIG. 6 is a 2-D SDS-PAGE gel of a protein mixture according to an embodiment of the present invention with circled proteins identified as in the legend;
- FIGS. 7 A-O are mass spectrometer results for tryptic fragments from one dimensional (1-D) gels of a protein mixture according to an embodiment of the present invention.
- FIG. 8 is a 2-D gel Western blot of a protein mixture according to an embodiment of the present invention labeled with anti-phosphotyrosine antibody;
- FIGS. 9 A-D are 2-D gel Western blots of a protein mixture according to an embodiment of the present invention, labeled with indicated antibodies.
- FIG. 9A indicates the presence of BMP-3 and BMP-2.
- FIG. 9B indicates the presence of BMP-3 and BMP-7.
- FIG. 9C indicates the presence of BMP-7 and BMP-2, and
- FIG. 12D indicates the presence of BMP-3 and TGF- ⁇ 1;
- FIG. 10 is a PAS (periodic acid schiff) stained SDS-PAGE gel of HPLC fractions of a protein mixture according to an embodiment of the present invention.
- FIG. 11 is an anti-BMP-7 stained SDS-PAGE gel of a PNGase F treated protein mixture according to an embodiment of the present invention.
- FIG. 12 is an anti-BMP-2 stained SDS-PAGE gel of a PNGase F treated protein mixture according to an embodiment of the present invention.
- FIGS. 13 A-B are bar charts showing explant mass of glycosylated components in a protein mixture according to an embodiment of the present invention ( FIG. 13A ) and ALP score ( FIG. 13B ) of the same components;
- FIG. 14 is a chart showing antibody listing and reactivity
- FIGS. 15 A-B together comprise a chart showing tryptic fragment sequencing data for components of a protein mixture according to an embodiment of the present invention
- FIGS. 16 A-F together comprise a chart showing tryptic fragment mass spectrometry data for components of a protein mixture according to an embodiment of the present invention
- FIGS. 17 A-B are an SDS-gel ( FIG. 17B ) and a scanning densitometer scan ( FIG. 17A ) of the same gel for a protein mixture according to an embodiment of the present invention
- FIG. 18 is a chart illustrating the relative mass, from scanning densitometer quantification, of protein components in a protein mixture according to an embodiment of the present invention.
- FIGS. 19 A-D together comprise a chart showing mass spectrometry data of various protein fragments from 2D gels of a protein mixture according to an embodiment of the present invention
- FIGS. 20 A-C show the results of a quail chorioallantoid membrane (CAM) angiogenesis assay of a protein mix according to the present invention
- FIG. 21 shows the vascular growth in the CAM of FIGS. 20 A-C
- FIGS. 22 A-E are histological sections of blood vessels formed in the canine myocardium following treatment with a protein mix in accordance with the present invention.
- FIGS. 23 and 24 are in vivo angiograms showing blood flood to a representative LAD after placement of an ameroid constrictor on the LAD and occlusion the LAD but before treatment according to the present invention.
- FIGS. 25 and 26 are in vivo angiograms showing blood flood to a representative LAD after placement of an ameroid constrictor on the LAD and occlusion the LAD and six weeks after treatment according to the present invention.
- Angiogenesis is a complex process involving several different cell types and molecular signaling events. Endothelial cells must secrete proteases to dissolve cell-cell and cell-matrix attachments, migrate and proliferate to form new vascular branches. Although single factors such as bFGF and VEGF have shown promise as angiogenic agents, it has been discovered that a more robust angiogenic response may be obtained through the use of an agent that comprises a mixture of proteins. This may be due in part to a synergistic effect of the combined proteins on the subject tissue. Thus, according to a preferred embodiment of the present invention, a natural bypass effect is achieved by injecting an angiogenic mixture of bone proteins into tissue in need of increased blood flow.
- a natural bypass effect is promoted by administering a mammal a mixture of growth factors derived from bone.
- vessel growth is promoted so as to heal a heart artery that has been blocked.
- angiogenesis is promoted in ischemic tissue so as to assist in recovery.
- the bone-derived angiogenic protein (BDAP) mixture preferred for use in the present invention is preferably administered directly to ischemic tissue in a suitable carrier.
- a suitable carrier for example, in some instances, it may be desired to apply the angiogenic factor in a carrier that allows it to be absorbed quickly, while in other instances it may be desired to apply the angiogenic factor in a controlled, time-release manner. In other instances, a single dose or other variation may be preferred.
- the preferred carrier material will vary depending on the desired clinical application or site of administration.
- Polylactic acid, polyglycolic acid and their copolymers, collagen, PLURONIC (polyoxyalkylene ether co-polymer surfactant), and povidone (polyvinylpyrrolidone) are all examples of biocompatible materials that can be combined with BDAP mixtures to stimulate angiogenesis.
- a preferred angiogenic mixture of bone proteins is produced by a multi-step process that includes an ultrafiltration step, an anion exchange chromatography step, a cation exchange chromatography step and a high performance liquid chromatography (HPLC) purification step as described in detail below.
- Preferred processes for producing the angiogenic protein mixtures of the present invention are described in full detail in U.S. Pat. Nos. 5,290,763 and 5,371,191, which are incorporated herein in their entireties. The processes can be summarized as follows. In a first step, demineralized bone particles from a suitable source (such as crushed bovine bone) are subjected to protein extraction using guanidine hydrochloride. The extract solution is filtered, and subjected to a two step ultrafiltration process.
- a suitable source such as crushed bovine bone
- an ultrafiltration membrane having a nominal molecular weight cut off (MWCO) of 100 kD is preferably employed.
- the retentate is discarded and the filtrate is subjected to a second ultrafiltration step using an ultrafiltration membrane preferably having a nominal MWCO of about 10 kD.
- the retentate is then subjected to diafiltration to substitute urea for guanidine.
- the protein-containing urea solution is then subjected to sequential ion exchange chromatography, first anion exchange chromatography followed by cation exchange chromatography.
- a strongly cationic resin is used, preferably having quaternary amine functional groups.
- the eluant for the anion exchange process has a conductivity from about 10,260 micromhos ( ⁇ mhos) (1.026 ⁇ 10 ⁇ 2> siemens (S)) to about 11,200 ⁇ mhos (1.120 ⁇ 10 ⁇ 31 2>S).
- a strongly anionic resin is used, preferably having sulfonic acid functional groups.
- the eluant for the cation exchange process typically has a conductivity from about 39,100 ⁇ mhos (3.91 ⁇ 10 ⁇ 2>S) to about 82,700 ⁇ mhos ( 8.27 ⁇ 10 ⁇ 2>S) or more.
- the proteins are advantageously kept in solution.
- the proteins produced by the above process are then subjected to HPLC.
- the HPLC process preferably utilizes a column containing hydrocarbon-modified silica packing material.
- the proteins can be loaded onto the HPLC column in a solution of aqueous trifluoracetic acid or other suitable solvent, such as heptafluorobutyric acid, hydrochloric or phosphoric acid.
- a trifluoracetic acid solution having a concentration of from about 0.05 percent by volume to about 0.15 percent by volume, and more preferably about 0.1 percent by volume trifluoracetic acid is used.
- Proteins are eluted from the HPLC column with an organic solvent/water mixture suitable for obtaining the desired proteins.
- a preferred eluant in the HPLC process is an acetonitrile solution.
- the preferred eluant typically has an acetonitrile concentration which varies, during elution, from about 30 percent by volume to about 45 percent by volume.
- the acetonitrile concentration in the eluant is increased in increments of between about 0.30 percent by volume and about 0.40 percent by volume per minute until the desired highest concentration of acetonitrile is achieved.
- Proteins can be recovered from the HPLC process eluant by means generally known in the art.
- a preferred angiogenic fraction of the eluted proteins occurs when the acetonitrile concentration in the eluant is between about 33 percent by volume and about 37 percent by volume.
- the purification processes described above yield novel angiogenic protein mixtures. Because they comprise mixtures of proteins, these angiogenic factors are most easily described in terms of their properties. Hence, in one embodiment of the present angiogenic factor, the factor is a mixture of a number of proteins having the sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) profile shown in FIG. 1 .
- SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
- Another characterization of the present invention is a mixture of proteins having a preferred amino acid composition of about 20-25 mole percent of acidic amino acids [ASP(+ASN) and GLU(+GLN)]; about 10-15 mole percent of hydroxy amino acids (SER and THR); about 35-45 mole percent aliphatic amino acids (ALA, GLY, PRO, MET, VAL, ILE, and LEU); about 4-10 mole percent aromatic amino acids (TYR and PHE); and about 10-20 mole percent basic amino acids (HIS, ARG and LYS).
- this embodiment of the angiogenic protein mixture amino preferably has an amino acid composition of about 23.4 mole percent of acidic amino acids [ASP(+ASN) and GLU(+GLN)]; about 13.5 mole percent of hydroxy amino acids (SER and THR); about 40.0 mole percent aliphatic amino acids (ALA, GLY, PRO, MET, VAL, ILE, and LEU); about 6.8 mole percent aromatic amino acids (TYR and PHE); and about 16.6 mole percent basic amino acids (HIS, ARG and LYS). (TRP, CYS and 1/2 CYS were not measured and are not included in the calculation of mole percent.)
- An alternative embodiment of the present angiogenic factor can be defined as a different fraction of the total protein stream exiting the HPLC process. More particularly, the proteins eluted when the eluant has an acetonitrile concentration of from about 37 to about 39.5 percent by volume have been found to have surprising angiogenic activity. The mixture defined in this manner contains hundreds of natural proteins. It is believed that the angiogenic activity of proteins obtained in this manner may be further enhanced by selecting smaller fractions of the eluant and quantitatively comparing the angiogenic activity of each fraction.
- HPLC high performance liquid chromatography
- SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
- FIG. 2 Size standards (ST) of 14, 21, 31, 45, 68 and 97 kDa were obtained as Low range size standards from BIORADTM and are shown at either end of the coomassie blue stained gel.
- HPLC fractions 29 through 34 are pooled to produce BP (see boxes, FIGS. 2 and 3 ), as shown in a similarly prepared SDS-PAGE gel in FIG. 17B .
- BP protein kinase
- the various components of BP were characterized by mass spectrometry and amino acid sequencing of tryptic fragments where there were sufficient levels of protein for analysis.
- the major bands in the ID gel (as numerically identified in FIG. 3 ) were excised, eluted, subjected to tryptic digestion and the fragments were HPLC purified and sequenced.
- the sequence data was compared against known sequences, and the best matches are shown in FIGS. 12 A-B. These identifications are somewhat tentative, in that only portions of the entire proteins have been sequenced and, in some cases, there is variation between the human and bovine analogs for a given protein.
- FIGS. 7 A-O The same tryptic protein fragments were analyzed by mass spectrometry and the mass spectrograms are shown in FIGS. 7 A-O.
- the tabulated results and homologies are shown in FIGS. 16 A-F, which provide identification information for the bands identified in FIGS. 3-4 .
- assignment of spot identity may be tentative based on species differences and post translational modifications.
- a summary of all protein identifications for 1d gels is shown in FIG. 4 .
- FIGS. 17A and 17B are stained SDS-PAGE gel of BP and FIG. 17A represents a scanning densitometer trace of the same gel.
- the identified proteins were labeled and quantified by measuring the area under the curve. These results are presented in FIG. 18 as a percentage of the total peak area.
- BP SDS-PAGE gel representing about 60% of the protein in BP.
- the identified proteins fall roughly into three categories: the ribosomal proteins, the histones, and growth factors, including bone morphogenic factors (BMPs). It is expected that he ribosomal proteins may be removed from the BP without loss of activity, since these proteins are known to have no growth factor activity. Upon this separation, the specific activity is expected to increase correspondingly.
- BMPs bone morphogenic factors
- histone and ribosomal proteins may be removed from the BP with no resulting loss, or even with an increase, in specific activity. It is expected that histones can removed from the BP cocktail by immunoaffinity chromatography, using either specific histone protein antibodies or a pan-histone antibody.
- the histone depleted BP (BP-H) produced in this manner may be suitable for wound healing.
- the mixture produced when the known ribosomal proteins are stripped from the BP cocktail (BP-R) may be suitable for wound healing.
- An SDS-PAGE gel of BP was also analyzed by Western immunoblot with a series of antibodies, as listed in FIG. 14 . Visualization of antibody reactivity was by horseradish peroxidase conjugated to a second antibody and using a chemiluminescent substrate. Further, TGF- ⁇ 1 was quantified using commercially pure TGF- ⁇ 1 as a standard and was determined to represent less than 1% of the BP protein The antibody analysis indicated that each of the proteins listed in FIG. 14 is present in BP.
- the BP was further characterized by 2-D gel electrophoresis, as shown in FIGS. 5-6 .
- the proteins are separated in horizontal direction according to charge (pI) and in the vertical direction by size as described in two-dimensional electrophoresis adapted for resolution of basic proteins was performed according to the method of O'Farrell et al. (O'Farrell, P. Z., Goodman, H. M. and O'Farrell, P. H., Cell, 12: 1133-1142, 1977) by the Kendrick Laboratory (Madison, Wis.). Two-dimensional gel electrophoresis techniques are known to those of skill in the art.
- Non-equilibrium pH gradient electrophoresis (“NEPHGE”) using 1.5% pH 3.5-10, and 0.25% pH 9-11 ampholines (Amersham Pharmacia Biotech, Piscataway, N.J.) was carried out at 200 V for 12 hrs. Purified tropomyosin (lower spot, 33,000 KDa, pI 5.2), and purified lysozyme (14,000 KDa, pI 10.5-11) (Merck Index) were added to the samples as internal pI markers and are marked with arrows.
- NEPHGE Non-equilibrium pH gradient electrophoresis
- FIG. 5 shows the stained 2-D gel with size standards indicated on the left. Tropomyosin (left arrow) and lysozyme (right arrow) are also indicated.
- FIG. 6 The same gel is shown in FIG. 6 with several identified proteins indicated by numbered circles.
- the proteins were identified by mass spectrometry and amino acid sequencing of tryptic peptides, as described above.
- the identity of each of the labeled circles is provided in the legend of FIG. 6 and the data identifying the various protein spots is presented in FIGS. 19 A-D.
- FIG. 8 shows a 2-D gel, electroblotted onto filter paper and probed with a phosphotyrosine mouse monoclonal antibody by SIGMA (# A-5964). Several proteins were thus shown to be phosphorylated at one or more tyrosine residues.
- FIGS. 9 A-D Similar 2-D electroblots were probed with BP component specific antibodies, as shown in FIGS. 9 A-D.
- the filters were probed with BMP-2, BMP-3 ( FIG. 9A ), BMP-3, BMP-7 ( FIG. 9B ), BMP-7, BMP-2 ( FIG. 9C ), and BMP-3 and TGF- ⁇ 1 ( FIG. 9D ).
- Each shows the characteristic, single-size band migrating at varying pI, as is typical of a protein existing in various phosphorylation states.
- BP in 10 mM HCl was incubated overnight at 37° C. with 0.4 units of acid phosphatase (AcP).
- AcP acid phosphatase
- Treated and untreated samples were added to lyophilized discs of type I collagen and evaluated side by side in the subcutaneous implant rat bioassay, as previously described in U.S. Pat. Nos. 5,290,763, 5,563,124 and 5,371,191.
- 10 (g of BP in solution was added to lyophilized collagen discs and the discs implanted subcutaneously in the chest of a rat.
- the discs were then recovered from the rat at 2 weeks for the alkaline phosphotase (“ALP”—a marker for bone and cartilage producing cells) assay or at 3 weeks for histological analysis.
- ALP alkaline phosphotase
- the explants were homogenized and levels of ALP activity measured using a commercial kit.
- histology thin sections of the explant were cut with a microtome, and the sections stained and analyzed for bone and cartilage formation.
- FIG. 10 shows an SDS-PAGE gel stained with periodic acid schiff (PAS)—a non-specific carbohydrate stain, indicating that several of the BP components are glycosylated (starred protein identified as BMP-3).
- FIGS. 11-12 show immunodetection of two specific proteins (BMP-7, FIG. 14 and BMP-2, FIG. 15 ) treated with increasing levels of PNGase F (Peptide-N-Glycosidase F). Both BMP-2 and BMP-7 show some degree of glycoslyation in BP, but appear to have some level of protein resistant to PNGase F as well (plus signs indicate increasing levels of enzyme). Functional activity of PNGase F and sialadase treated samples were assayed by explant mass and by ALP score, as shown in FIGS. 13A and 13B , which shows that glycosylation is required for full activity.
- PNGase F and sialadase treated samples were assayed by explant mass and by ALP score,
- BMPs 2, 3 and 7 are modified by phosphorylation and glycosylation. These post-translation modifications affect protein morphogenic activity, 33% and 50% respectively, and care must be taken in preparing BP not to degrade these functional derivatives.
- Quail chorioallantoic membrane was in the manner described in “A Novel Assay of Angiogenesis in the Quail Chorioallantoic Membrane: Stimulation by bFGF and Inhibition by Angiostatin According to Fractal Dimension and Grid Intersection,” Parsons-Wingerter P., Dwai B., Yang M C., Elliot K E., Milaninia A., Redlitz A., Clark J. and Sage E. H. Fertilized Japanese quail eggs ( Coturnix coturnix japonica ) were opened onto Petri dishes on day 3 post-incubation ( FIG. 20A ).
- a BDAP mixture diluted in PBS/ovalubumin prewarmed to 37° C., was distributed evenly onto the surface of the CAM. After 24 hours of incubation, the CAM's were fixed, dissected and photographed ( FIG. 20B ) at 10 ⁇ magnification to visualize the arterial vascular tree, including endstage vessels. Digital images of triplicate CAM specimens were acquired at lOx magnification in grayscale, binarized to black-and-white, and skeletonized ( FIG. 20C ). The vessel branching pattern was analyzed and quantified by the fractal dimension.
- the photographs in FIG. 21 are representative digital binarized images of CAMs exposed to 10 ⁇ g/ml dose of growth factor for 24 hours. Quantitative data corresponding to these images were acquired by analyzing the skeletonized images and determining the fractal dimension of the branched vascular pattern. Data were pooled from two separate experiments consisting of three CAMs per experiment. Exposure to BDAP resulted in 124% greater mean angiogenic stimulation over the basal rate (defined as the change in fractal dimension in untreated controls) versus a 43% increase over basal rate for bFGF-treated CAMs. (p ⁇ 0.006).
- bromodeoxyuridine (BrdU, 25 mg/kg, Sigma, St. Louis, Mo.) was administered subcutaneously on post-operative days 2, 4, 6, 8, 10, 12, 14 and 21. After two or six weeks, the dogs were euthanized and the hearts explanted and cut into samples. Samples were fixed and serial sections, 4-5 microns thick, were cut and stained with Masson's trichrome stain to evaluate the general morphology of the myocardium. Sister sections were stained using standard immunohistochemical techniques with antibodies against bromodeoxyuridine (BrdU), PC10 proliferating cell nuclear antigen (PCNA), alpha smooth muscle actin (SMA) and Factor VIII using standard techniques.
- PCNA PC10 proliferating cell nuclear antigen
- SMA alpha smooth muscle actin
- GFm Sulzer's Growth Factor mixture
- ProVascTM Sulzer's Growth Factor mixture
- 38 dogs underwent ameroid constrictor placement on the proximal LAD and ligation of visible epicardial vessels collateralizing the LAD territory.
- animals had intramyocardial injections of either placebo, GFm at a concentration of 1 mg/ml or GFm at a concentration of 10 mg/ml.
- Each injection consisted of 0.15 ml, injections were at a spatial density of ⁇ 1/cm2 over the LAD region.
- Dye-Trak® Colored Microspheres (15 ⁇ 0.1 ⁇ m diameter, suspension in saline solution, 0.5% Tween 80 and 0.1% Thimerosal as a bacteriostat; Triton Technology Inc., San Diego, Calif.) provide a non-radioactive method of measuring regional blood flow. These precision, highly uniform spheres are quantified by spectrophotometry and were used to determine coronary blood flow at rest and during maximum adenosine stress. After randomization of colors, resting blood flow was assessed using rapid infusion of a set of microspheres (COLOR 1, 2 ml, 6 ⁇ 10 6 spheres) through the previously placed left atrial line.
- the syringe was connected to the infusion line.
- Each echocardiogram was performed by one of 3 experienced echocardiographers completely blinded to group assignment.
- Animal names, ID numbers, time and dobutamine infusion rates were annotated on the video recording of each study.
- Baseline recordings under resting conditions at 4 different levels (basal, mid-papillary, low-papillary and apical; see FIG. 7 ) at each dobutamine infusion rate were acquired (HP Sonos 5500®, S4 transducer 2-2.5 MHz, Hewlett Packard, Andover, Mass.) from a parastemal short axis window.
- mice were randomly assigned to one of the 3 treatment groups: placebo, low concentration GFm or high concentration GFm.
- 21 envelopes each containing a single treatment group assignment (7 for each group, approximately equally distributed between male and female) were prepared and randomly ordered; each envelope was labeled “male” or “female” so as to guide animal recruitment through the course of the study.
- an envelope from the stack corresponding to the gender of the animal was randomly chosen from those remaining and was opened by an investigator independent of all other aspects of the investigation.
- each dog was anesthetized using the same anesthetic protocol as for the first surgery.
- Urine samples were obtained using either a urinary catheter or a suprapubic cannula and these were submitted for routine analysis. If possible, the samples were taken prior to angiography. If the bladder was empty, urine had to be withdrawn after surgery.
- the right femoral artery was surgically exposed and a standard left coronary artery catheter 1 was introduced under fluoroscopic guidance through the artery into the left main coronary artery.
- Angiography was performed 2 using standard views to visualize the left anterior descending artery (LAD) and diagonal vessels. These sequences were recorded on VHS videotape.
- Animals in Group 1 received intramyocardial GF m injections at a GF m concentration of 1 mg/ml, 0.15 ml/injection, 1 injection/cm 2 to the LAD region, total of 15-20 injections per heart.
- Group 2 animals received intramyocardial GF m injections, at a GF m concentration of 10 mg/ml, 0.15 ml/injection, 1 injection/cm 2 to the LAD region, total of 15-20 injections per heart.
- Group 3 animals received intramyocardial injections of vehicle (1% LMW Povidone) without GF m , 0.15 ml/injection, 1 injection/cm 2 to the LAD region, total of 15-20 injections per heart. Injection solutions were prepared by two individuals who were independent of the group of investigators performing the surgeries and follow-up tests. A shallow stitch (4-0 Prolene® taper RB-1 monofilament polypropylene suture, Ethicon, Inc., Somerville, N.J.) was placed over each injection site so that each site could be identified when the heart was removed 6 weeks later. After completing the injections, the heart surface was photographed in order to document the injection site placement.
- vehicle 1% LMW Povidone
- mice were anesthetized as described above, urine samples were collected in the same manner as during the second surgery and angiography was repeated using the left femoral artery to introduce the coronary catheter. Images were recorded on VHS tape for off-line analysis. After completing the angiography, the animal was sacrificed with an overdose of phenobarbital and the heart was removed. Three transmural tissue blocks, each containing 1 or 2 injection sites (identified by the previously placed epicardial stitches) were isolated in individual transmural tissue blocks.
- Angio angiography
- Histo histology
- Echo D descriptive echocardiographic findings
- Echo WM change in echocardiographic wall motion score
- ⁇ FAC change in fractional area shortening from echocardiography
- CMS percent change in blood flow from colored microsphere analysis
- Angiography was graded on a 3 point semiquantitative scale: 0, no improvement; 1+ mild improvement in distal LAD visualization; 2+ significant improvement in distal LAD visualization.
- FIGS. 23-26 illustrate the marked improvement in blood flow that resulted from treatment with the inventive composition.
- the angiograms are taken at the beginning of the marking process, while the angiograms of FIGS. 24 and 26 are taken after a significant of the radio-opaque marker has been injected.
- the visible portion of the LAD is relatively short, indicating that the radio-opaque marker has not entered the LAD.
- the LAD is much more visible in FIG. 26 , indicating that blood is flowing in the region. Comparing FIGS.
- EchoD was a semiquantitative descriptive parameter obtained by having an experienced echocardiographer examining changes in the individual wall motion scores between baseline and the final study (CE 3). EchoD was a 3 point scale: ⁇ 1, worsened wall motion during stress; 0, no change in wall motion during stress; 1+ improved wall motion during stress. This parameter tended to decrease in the high concentration group but this was not statistically significant. EchoWM was the change in the sum of wall motion scores; a lower number for this parameter indicates better function. Similar to the EchoD parameter, there was a slight decrease in function detected in the high concentration group. The third parameter was the change in the percent fractional shortening showed no significant difference between groups.
- CE 1 Rest Ischemia 0.76 ⁇ 0.06* 0.91 ⁇ 0.17 0.90 ⁇ 0.10 Borderzone 0.84 ⁇ 0.11 0.92 ⁇ 0.16 1.04 ⁇ 0.13 Control area 0.94 ⁇ 0.07 0.95 ⁇ 0.15 1.18 ⁇ 0.12
- CE 1 Stress Ischemia 1.66 ⁇ 0.18* 1.83 ⁇ 0.19* 1.79 ⁇ 0.15* Border zone 2.55 ⁇ 0.26*# 2.39 ⁇ 0.29*# 2.49 ⁇ 0.17*# Control area 4.07 ⁇ 0.53 3.70 ⁇ 0.37 4.29 ⁇ 0.36
- CE 3 Rest Ischemia 0.70 ⁇ 0.05* 1.07 ⁇ 0.25* 0.90 ⁇ 0.12* Border zone 0.85 ⁇
- angiogenic factors in accordance with the present invention has several advantages over the alternative methods for inducing angiogenesis, such as inflammation resulting from laser injury.
- the growth factors of the present invention can be delivered in a minimally invasive manner to ischemic tissues either through a thoracotomy or percutaneous catheterization without the use of expensive equipment.
- the process for manufacturing the present angiogenic factors can be readily scaled up to a commercial production scale.
- a further advantage is that the proteins are kept in solution during the purification steps and exhibit little deterioration during the production process.
- Another advantage is that the resultant mixture of proteins can be used directly, without the mixing that may be required with proteins produced by other processes.
Abstract
An angiogenic factor comprising a mixture of proteins derived from bone. The angiogenic protein mixture is produced by a series of steps that allow the proteins to be kept in solution. The angiogenic mixture of bone proteins is produced by a multi-step process that includes at least one ultrafiltration step, an anion exchange chromatography step, a cation exchange chromatography step and a high performance liquid chromatography (HPLC) purification step.
Description
- This application is a continuation-in-part of U.S. Ser. No. 09/173,989, filed Oct. 16, 1998 and entitled “Protein Mixtures to Induce Therapeutic Angiogenesis,” which is incorporated herein by reference.
- Not applicable.
- The present invention relates to a method for inducing the growth of blood vessels in instances where it is desirable to increase the supply of blood to a portion of a living body. More particularly, the present invention comprises a novel angiogenic factor. Still more particularly, the present invention relates to the use of mixtures of protein extracted from bone to cause a natural vascular bypass effect.
- There are many medical circumstances in which an increase in the supply of blood to living tissue is indicated. These include: bums and wound healing, in which the incorporation of angiogenic factors into artificial skin may facilitate the formation of blood vessels in the healing wound and reduce the risk of infection; cardiovascular disease, in which repair of anginal or ischemic cardiac tissue can be effected by causing the ingrowth of new blood vessels; stroke, where increased blood supply to the brain can reduce the risk of transient ischemic attack and/or cerebral arterial deficiency; and peripheral vascular disease, in which blood flow in the extremities is diminished. In each case, it is believed that the growth of new blood vessels will increase the volume of blood circulating through the tissue in question, and correspondingly increase the amount of oxygen and nutrients available to that tissue.
- One common cause of decreased blood flow is atherosclerosis. Atherosclerosis affects the blood vessels, including those of the heart, and is a major cause of cardiovascular disease, stroke and peripheral vascular disease. This disease may have its beginnings early in life and is first noted as a thickening of the arterial walls. This thickening is an accumulation of fat, fibrin, cellular debris and calcium. The resultant narrowing of the lumen of the afflicted vessel is called stenosis. Stenosis impedes and reduces blood flow. Hypertension and dysfunction of the organ or area of the body that suffers the impaired blood flow can result. As the buildup on the inner wall of a vessel thickens, the vessel wall loses the ability to expand and contract. Also, the vessel loses its viability and becomes weakened and susceptible to bulging, also known as aneurysm. In the presence of hypertension or elevated blood pressure, aneurysms will frequently dissect and ultimately rupture.
- Small vessels, such as the arteries that supply blood to the heart, legs, intestines and other areas of the body, are particularly susceptible to atherosclerotic narrowing. When an artery in the leg or intestine is affected, the resultant loss of blood supply to the leg or segment of the intestine may result in gangrene. Atherosclerotic narrowing of one or more of the coronary arteries limits and in some instances prevents blood flow to portions of the heart muscle. Depending upon the severity of the occlusion and its location within the coronary circulation system, pain, cardiac dysfunction or death may result. Because the consequences of blocked arteries are so serious, reliable treatments are highly desirable.
- In many instances, it is possible to correct aneurysms and stenosis of major arteries using plastic reconstruction that does not require any synthetic graft or patch materials. In other instances, such as where the disease is extensive and the vessel is no longer reliable, the blocked or weakened portion of the vessel is usually replaced with a graft. In such case, the affected vessel section is transected and removed and a synthetic patch, conduit or graft is sewn into its place. These types of procedures, including coronary artery bypass grafting (CABG) and percutaneous transluminal coronary angioplasty (PTCA), are routinely performed for the purpose of alleviating ischemia.
- Nevertheless, coronary artery disease alone is responsible for approximately 550,000 deaths each year in the United States. Peripheral vascular disease results in lower limb amputation in about 150,000 patients each year, with a subsequent mortality rate of 40% within two years of amputation. Some of the difficulty in treating arterial occlusion may lie in the fact that each of these surgical procedures is associated with a certain incidence of restenosis and may not be appropriate in certain instances. This is particularly true when the patient is elderly or has undergone a previous CABG or PTCA procedure. Furthermore, in such cases, a less invasive technique would be preferred. In particular, it would be advantageous to be able to stimulate the surrounding tissue to produce for itself new vessels that would compensate for the occluded vessels.
- While angiogenic, or “vessel-growing,” factors in general have been the subject of much research, no angiogenic factor has yet been found to be effective for promoting the desired natural bypass effect. Examples of such growth factors are transforming growth factor beta (TGF-β), osteonectin or SPARC, platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF). All of these growth factors are either synthetic, meaning they are manufactured chemically from non-living sources, or are produced by recombinant manufacturing processes. Each of these angiogenic factors comprises only a single protein and possesses only a single functionality. In addition, many of the known angiogenic compounds are exceedingly difficult and/or expensive to manufacture.
- Hence, it is desired to provide an effective angiogenic factor that is easy to manufacture from readily available materials, easily administered by the surgeon and effective at stimulating the growth of new blood vessels into the treated tissue.
- The present invention comprises an angiogenic factor that is easily manufactured from readily available materials, easily administered by the surgeon and effective at stimulating the growth of new blood vessels into the treated tissue. The angiogenic factor of the present invention comprises a group of proteins extracted from bone. It has been found that the mixtures of proteins produced by certain processes are particularly effective angiogenic agents. These angiogenic agents can be administered as part of the treatment of an existing vascular disorder, or can play a role in early intervention and prevention if administered in certain cases. In particular, the present angiogenic agents can be introduced into tissue in the vicinity of an occluded vessel so as to cause the formation of new vessels that bypass the occluded vessel. In this manner, a natural bypass mechanism is provided.
- The angiogenic mixtures of bone proteins used according to the present invention are produced by a multi-step process that includes at least one ultrafiltration step, an anion exchange chromatography step, a cation exchange chromatography step and a high performance liquid chromatography (HPLC) purification step.
- In particularly preferred embodiments, the invention provides a method for promoting natural bypass in a mammal so provide increased blood flow to tissue served by an occluded or partly occluded vessel, a method for promoting vessel growth to heal a heart artery that has been blocked, or a method for promoting angiogenesis to assist in recovery from tissue damage.
- In each instance, the method preferably comprises administering to the mammal a mixture of proteins derived from ground bone. The mixture of proteins preferably comprises at least two growth factors selected from the group consisting of bone morphogenic protein-2 (BMP-2), bone morphogenic protein-3 (BMP-3), bone morphogenic protein-4 (BMP-4), bone morphogenic protein-5 (BMP-5), bone morphogenic protein-6 (BMP-6), bone morphogenic protein-7 (BMP-7), transforming growth factor β1 (TGF-β1), transforming growth factor β2 (TGF-β2), transforming growth factor β3 (TGF-p3), and fibroblast growth factor 1 (FGF-1).
- The mammal to which the present method is applied can be a human, and the mixture can be administered subcutaneously, intramuscularly, or intravenously. The bone-derived protein mixture may be derived from bovine bone. The mixture can be administered discretely or continuously.
- In a preferred embodiment, the mixture further comprises a growth factor selected from insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF), hepatocyte growth factor (HGF), transforming growth factor α (TGF-α), or platelet-derived growth factor (PDGF), and optionally includes a preservative or an adjuvant. Particularly preferred mixtures comprises BMP-2, BMP-3, BMP-7, TGF-β, and FGF, or the mixture derived by (i) grinding mammalian bone, to produce ground bone; (ii) cleaning the ground bone, to produce cleaned ground bone; (iii) demineralizing the cleaned ground bone, to produce demineralized cleaned ground bone; (iv) extracting protein from the demineralized cleaned ground bone using a protein denaturant; to yield extracted protein; (v) ultrafiltering the extracted protein to separate out high molecular weight proteins; (vi) ultrafiltering the extracted protein to separate out low molecular weight proteins; (vii) transferring the extracted protein to a non-ionic denaturant; (viii) subjecting the extracted protein to an anion exchange process; (ix) subjecting the extracted protein to a cation exchange process; and (x) subjecting the extracted protein to a reverse phase HPLC process.
- For a more detailed description of the present invention, reference will now be made to the accompanying Figures, wherein:
-
FIG. 1 illustrates an SDS-PAGE of one embodiment of the present angiogenic protein mixture, both in reduced and non-reduced forms; -
FIG. 2 is an SDS-PAGE gel of HPLC fractions 27-36 of a protein mixture according to an embodiment of the present invention. -
FIG. 3 is an SDS-PAGE gel with identified bands indicated according to the legend ofFIG. 4 ; -
FIG. 4 is an SDS-PAGE gel of a protein mixture according to an embodiment of the present invention with identified bands indicated, as provided in the legend; -
FIG. 5 is a two dimensional (2-D) SDS-PAGE gel of a protein mixture according to an embodiment of the present invention with internal standards indicated by arrows; -
FIG. 6 is a 2-D SDS-PAGE gel of a protein mixture according to an embodiment of the present invention with circled proteins identified as in the legend; - FIGS. 7A-O are mass spectrometer results for tryptic fragments from one dimensional (1-D) gels of a protein mixture according to an embodiment of the present invention;
-
FIG. 8 is a 2-D gel Western blot of a protein mixture according to an embodiment of the present invention labeled with anti-phosphotyrosine antibody; - FIGS. 9A-D are 2-D gel Western blots of a protein mixture according to an embodiment of the present invention, labeled with indicated antibodies.
FIG. 9A indicates the presence of BMP-3 and BMP-2.FIG. 9B indicates the presence of BMP-3 and BMP-7.FIG. 9C indicates the presence of BMP-7 and BMP-2, andFIG. 12D indicates the presence of BMP-3 and TGF-β1; -
FIG. 10 is a PAS (periodic acid schiff) stained SDS-PAGE gel of HPLC fractions of a protein mixture according to an embodiment of the present invention; -
FIG. 11 is an anti-BMP-7 stained SDS-PAGE gel of a PNGase F treated protein mixture according to an embodiment of the present invention; -
FIG. 12 is an anti-BMP-2 stained SDS-PAGE gel of a PNGase F treated protein mixture according to an embodiment of the present invention; - FIGS. 13A-B are bar charts showing explant mass of glycosylated components in a protein mixture according to an embodiment of the present invention (
FIG. 13A ) and ALP score (FIG. 13B ) of the same components; -
FIG. 14 is a chart showing antibody listing and reactivity; - FIGS. 15A-B together comprise a chart showing tryptic fragment sequencing data for components of a protein mixture according to an embodiment of the present invention;
- FIGS. 16A-F together comprise a chart showing tryptic fragment mass spectrometry data for components of a protein mixture according to an embodiment of the present invention;
- FIGS. 17A-B are an SDS-gel (
FIG. 17B ) and a scanning densitometer scan (FIG. 17A ) of the same gel for a protein mixture according to an embodiment of the present invention; -
FIG. 18 is a chart illustrating the relative mass, from scanning densitometer quantification, of protein components in a protein mixture according to an embodiment of the present invention; - FIGS. 19A-D together comprise a chart showing mass spectrometry data of various protein fragments from 2D gels of a protein mixture according to an embodiment of the present invention;
- FIGS. 20A-C show the results of a quail chorioallantoid membrane (CAM) angiogenesis assay of a protein mix according to the present invention;
-
FIG. 21 shows the vascular growth in the CAM of FIGS. 20A-C; - FIGS. 22A-E are histological sections of blood vessels formed in the canine myocardium following treatment with a protein mix in accordance with the present invention;
-
FIGS. 23 and 24 are in vivo angiograms showing blood flood to a representative LAD after placement of an ameroid constrictor on the LAD and occlusion the LAD but before treatment according to the present invention; and -
FIGS. 25 and 26 are in vivo angiograms showing blood flood to a representative LAD after placement of an ameroid constrictor on the LAD and occlusion the LAD and six weeks after treatment according to the present invention. - Angiogenesis is a complex process involving several different cell types and molecular signaling events. Endothelial cells must secrete proteases to dissolve cell-cell and cell-matrix attachments, migrate and proliferate to form new vascular branches. Although single factors such as bFGF and VEGF have shown promise as angiogenic agents, it has been discovered that a more robust angiogenic response may be obtained through the use of an agent that comprises a mixture of proteins. This may be due in part to a synergistic effect of the combined proteins on the subject tissue. Thus, according to a preferred embodiment of the present invention, a natural bypass effect is achieved by injecting an angiogenic mixture of bone proteins into tissue in need of increased blood flow.
- In one embodiment, a natural bypass effect is promoted by administering a mammal a mixture of growth factors derived from bone. In another embodiment, vessel growth is promoted so as to heal a heart artery that has been blocked. In still another embodiment, angiogenesis is promoted in ischemic tissue so as to assist in recovery.
- The bone-derived angiogenic protein (BDAP) mixture preferred for use in the present invention is preferably administered directly to ischemic tissue in a suitable carrier. For example, in some instances, it may be desired to apply the angiogenic factor in a carrier that allows it to be absorbed quickly, while in other instances it may be desired to apply the angiogenic factor in a controlled, time-release manner. In other instances, a single dose or other variation may be preferred. In general, the preferred carrier material will vary depending on the desired clinical application or site of administration. Polylactic acid, polyglycolic acid and their copolymers, collagen, PLURONIC (polyoxyalkylene ether co-polymer surfactant), and povidone (polyvinylpyrrolidone) are all examples of biocompatible materials that can be combined with BDAP mixtures to stimulate angiogenesis.
- Characterization of Preferred Growth Factors
- A preferred angiogenic mixture of bone proteins is produced by a multi-step process that includes an ultrafiltration step, an anion exchange chromatography step, a cation exchange chromatography step and a high performance liquid chromatography (HPLC) purification step as described in detail below. Preferred processes for producing the angiogenic protein mixtures of the present invention are described in full detail in U.S. Pat. Nos. 5,290,763 and 5,371,191, which are incorporated herein in their entireties. The processes can be summarized as follows. In a first step, demineralized bone particles from a suitable source (such as crushed bovine bone) are subjected to protein extraction using guanidine hydrochloride. The extract solution is filtered, and subjected to a two step ultrafiltration process. In the first ultrafiltration step, an ultrafiltration membrane having a nominal molecular weight cut off (MWCO) of 100 kD is preferably employed. The retentate is discarded and the filtrate is subjected to a second ultrafiltration step using an ultrafiltration membrane preferably having a nominal MWCO of about 10 kD. The retentate is then subjected to diafiltration to substitute urea for guanidine. The protein-containing urea solution is then subjected to sequential ion exchange chromatography, first anion exchange chromatography followed by cation exchange chromatography. For the anion exchange process, a strongly cationic resin is used, preferably having quaternary amine functional groups. Typically, the eluant for the anion exchange process has a conductivity from about 10,260 micromhos (μmhos) (1.026×10<−2> siemens (S)) to about 11,200 μmhos (1.120×10<31 2>S). For the cation exchange process, a strongly anionic resin is used, preferably having sulfonic acid functional groups. The eluant for the cation exchange process typically has a conductivity from about 39,100 μmhos (3.91×10<−2>S) to about 82,700 μmhos (8.27×10<−2>S) or more.
- In the process described above, the proteins are advantageously kept in solution. According to the present invention, the proteins produced by the above process are then subjected to HPLC. The HPLC process preferably utilizes a column containing hydrocarbon-modified silica packing material. The proteins can be loaded onto the HPLC column in a solution of aqueous trifluoracetic acid or other suitable solvent, such as heptafluorobutyric acid, hydrochloric or phosphoric acid. Preferably, a trifluoracetic acid solution having a concentration of from about 0.05 percent by volume to about 0.15 percent by volume, and more preferably about 0.1 percent by volume trifluoracetic acid is used.
- Proteins are eluted from the HPLC column with an organic solvent/water mixture suitable for obtaining the desired proteins. A preferred eluant in the HPLC process is an acetonitrile solution. The preferred eluant typically has an acetonitrile concentration which varies, during elution, from about 30 percent by volume to about 45 percent by volume. In preferred embodiments, the acetonitrile concentration in the eluant is increased in increments of between about 0.30 percent by volume and about 0.40 percent by volume per minute until the desired highest concentration of acetonitrile is achieved. Proteins can be recovered from the HPLC process eluant by means generally known in the art. A preferred angiogenic fraction of the eluted proteins occurs when the acetonitrile concentration in the eluant is between about 33 percent by volume and about 37 percent by volume.
- The purification processes described above yield novel angiogenic protein mixtures. Because they comprise mixtures of proteins, these angiogenic factors are most easily described in terms of their properties. Hence, in one embodiment of the present angiogenic factor, the factor is a mixture of a number of proteins having the sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) profile shown in
FIG. 1 . - Another characterization of the present invention is a mixture of proteins having a preferred amino acid composition of about 20-25 mole percent of acidic amino acids [ASP(+ASN) and GLU(+GLN)]; about 10-15 mole percent of hydroxy amino acids (SER and THR); about 35-45 mole percent aliphatic amino acids (ALA, GLY, PRO, MET, VAL, ILE, and LEU); about 4-10 mole percent aromatic amino acids (TYR and PHE); and about 10-20 mole percent basic amino acids (HIS, ARG and LYS). More particularly, this embodiment of the angiogenic protein mixture amino preferably has an amino acid composition of about 23.4 mole percent of acidic amino acids [ASP(+ASN) and GLU(+GLN)]; about 13.5 mole percent of hydroxy amino acids (SER and THR); about 40.0 mole percent aliphatic amino acids (ALA, GLY, PRO, MET, VAL, ILE, and LEU); about 6.8 mole percent aromatic amino acids (TYR and PHE); and about 16.6 mole percent basic amino acids (HIS, ARG and LYS). (TRP, CYS and 1/2 CYS were not measured and are not included in the calculation of mole percent.)
- An alternative embodiment of the present angiogenic factor can be defined as a different fraction of the total protein stream exiting the HPLC process. More particularly, the proteins eluted when the eluant has an acetonitrile concentration of from about 37 to about 39.5 percent by volume have been found to have surprising angiogenic activity. The mixture defined in this manner contains hundreds of natural proteins. It is believed that the angiogenic activity of proteins obtained in this manner may be further enhanced by selecting smaller fractions of the eluant and quantitatively comparing the angiogenic activity of each fraction.
- In addition to the foregoing, BP has been partially characterized as follows: high performance liquid chromatography (HPLC) fractions have been denatured, reduced the DTT, and separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). One minute HPLC fractions from 27 to 36 minutes are shown in
FIG. 2 . Size standards (ST) of 14, 21, 31, 45, 68 and 97 kDa were obtained as Low range size standards from BIORAD™ and are shown at either end of the coomassie blue stained gel. In the usual protocol,HPLC fractions 29 through 34 are pooled to produce BP (see boxes,FIGS. 2 and 3 ), as shown in a similarly prepared SDS-PAGE gel inFIG. 17B . - The various components of BP were characterized by mass spectrometry and amino acid sequencing of tryptic fragments where there were sufficient levels of protein for analysis. The major bands in the ID gel (as numerically identified in
FIG. 3 ) were excised, eluted, subjected to tryptic digestion and the fragments were HPLC purified and sequenced. The sequence data was compared against known sequences, and the best matches are shown in FIGS. 12A-B. These identifications are somewhat tentative, in that only portions of the entire proteins have been sequenced and, in some cases, there is variation between the human and bovine analogs for a given protein. - The same tryptic protein fragments were analyzed by mass spectrometry and the mass spectrograms are shown in FIGS. 7A-O. The tabulated results and homologies are shown in FIGS. 16A-F, which provide identification information for the bands identified in
FIGS. 3-4 . As above, assignment of spot identity may be tentative based on species differences and post translational modifications. A summary of all protein identifications for 1d gels is shown inFIG. 4 . - The identified protein components of BP, as described in FIGS. 15A-B, 16A-F and 19A-D, were quantified as shown in
FIGS. 17A and 17B .FIG. 17B is a stained SDS-PAGE gel of BP andFIG. 17A represents a scanning densitometer trace of the same gel. The identified proteins were labeled and quantified by measuring the area under the curve. These results are presented inFIG. 18 as a percentage of the total peak area. - Thus, there are 11 major bands in the BP SDS-PAGE gel, representing about 60% of the protein in BP. The identified proteins fall roughly into three categories: the ribosomal proteins, the histones, and growth factors, including bone morphogenic factors (BMPs). It is expected that he ribosomal proteins may be removed from the BP without loss of activity, since these proteins are known to have no growth factor activity. Upon this separation, the specific activity is expected to increase correspondingly.
- It is expected that the histone and ribosomal proteins may be removed from the BP with no resulting loss, or even with an increase, in specific activity. It is expected that histones can removed from the BP cocktail by immunoaffinity chromatography, using either specific histone protein antibodies or a pan-histone antibody. The histone depleted BP (BP-H) produced in this manner may be suitable for wound healing. Similarly, the mixture produced when the known ribosomal proteins are stripped from the BP cocktail (BP-R) may be suitable for wound healing.
- An SDS-PAGE gel of BP was also analyzed by Western immunoblot with a series of antibodies, as listed in
FIG. 14 . Visualization of antibody reactivity was by horseradish peroxidase conjugated to a second antibody and using a chemiluminescent substrate. Further, TGF-β1 was quantified using commercially pure TGF-β1 as a standard and was determined to represent less than 1% of the BP protein The antibody analysis indicated that each of the proteins listed inFIG. 14 is present in BP. - The BP was further characterized by 2-D gel electrophoresis, as shown in
FIGS. 5-6 . The proteins are separated in horizontal direction according to charge (pI) and in the vertical direction by size as described in two-dimensional electrophoresis adapted for resolution of basic proteins was performed according to the method of O'Farrell et al. (O'Farrell, P. Z., Goodman, H. M. and O'Farrell, P. H., Cell, 12: 1133-1142, 1977) by the Kendrick Laboratory (Madison, Wis.). Two-dimensional gel electrophoresis techniques are known to those of skill in the art. Non-equilibrium pH gradient electrophoresis (“NEPHGE”) using 1.5% pH 3.5-10, and 0.25% pH 9-11 ampholines (Amersham Pharmacia Biotech, Piscataway, N.J.) was carried out at 200 V for 12 hrs. Purified tropomyosin (lower spot, 33,000 KDa, pI 5.2), and purified lysozyme (14,000 KDa, pI 10.5-11) (Merck Index) were added to the samples as internal pI markers and are marked with arrows. - After equilibration for 10 min in buffer “0” (10% glycerol, 50 mM dithiothreitol, 2.3% SDS and 0.0625 M tris, pH 6.8) the tube gel was sealed to the top of a stacking gel which is on top of a 12.5% acrylamide slab gel (0.75 mm thick). SDS slab gel electrophoresis was carried out for about 4 hrs at 12.5 mA/gel.
- After slab gel electrophoresis two of the gels were coomassie blue stained and the other two were transferred to transfer buffer (12.5 mM Tris, pH 8.8, 86 mM Glycine, 10% MeoH) transblotted onto PVDF paper overnight at 200 mA and approximately 100 volts/two gels. The following proteins (Sigma Chemical Co., St. Louis, Mo.) were added as molecular weight standards to the agarose which sealed the tube gel to the slab gel: myosin (220,000 KDa), phosphorylase A (94,000 KDa), catalase (60,000 KDa), actin (43,000 KDa), carbonic anhydrase (29,000 KDa) and lysozyme (14,000 KDa).
FIG. 5 shows the stained 2-D gel with size standards indicated on the left. Tropomyosin (left arrow) and lysozyme (right arrow) are also indicated. - The same gel is shown in
FIG. 6 with several identified proteins indicated by numbered circles. The proteins were identified by mass spectrometry and amino acid sequencing of tryptic peptides, as described above. The identity of each of the labeled circles is provided in the legend ofFIG. 6 and the data identifying the various protein spots is presented in FIGS. 19A-D. - Because several of the proteins migrated at more than one size (e.g., BMP-3 migrating as 6 bands) investigations were undertaken to investigate the extent of post-translation modification of the BP components. Phosphorylation was measured by anti-phosphotyrosine immunoblot and by phosphatase studies.
FIG. 8 shows a 2-D gel, electroblotted onto filter paper and probed with a phosphotyrosine mouse monoclonal antibody by SIGMA (# A-5964). Several proteins were thus shown to be phosphorylated at one or more tyrosine residues. - Similar 2-D electroblots were probed with BP component specific antibodies, as shown in FIGS. 9A-D. The filters were probed with BMP-2, BMP-3 (
FIG. 9A ), BMP-3, BMP-7 (FIG. 9B ), BMP-7, BMP-2 (FIG. 9C ), and BMP-3 and TGF-β1 (FIG. 9D ). Each shows the characteristic, single-size band migrating at varying pI, as is typical of a protein existing in various phosphorylation states. - For the phosphatase studies, BP in 10 mM HCl was incubated overnight at 37° C. with 0.4 units of acid phosphatase (AcP). Treated and untreated samples were added to lyophilized discs of type I collagen and evaluated side by side in the subcutaneous implant rat bioassay, as previously described in U.S. Pat. Nos. 5,290,763, 5,563,124 and 5,371,191. Briefly, 10 (g of BP in solution was added to lyophilized collagen discs and the discs implanted subcutaneously in the chest of a rat. The discs were then recovered from the rat at 2 weeks for the alkaline phosphotase (“ALP”—a marker for bone and cartilage producing cells) assay or at 3 weeks for histological analysis. For ALP analysis of the samples, the explants were homogenized and levels of ALP activity measured using a commercial kit. For histology, thin sections of the explant were cut with a microtome, and the sections stained and analyzed for bone and cartilage formation.
- Both native- and phosphatase-treated BP samples were assayed for morphogenic activity by mass of the subcutaneous implant (explant mass) and ALP score. The results showed that AcP treatment reduced the explant mass and ALP score from 100% to about 60%. Thus, phosphorylation is important for BP activity.
- The BP was also analyzed for glycosylation.
FIG. 10 shows an SDS-PAGE gel stained with periodic acid schiff (PAS)—a non-specific carbohydrate stain, indicating that several of the BP components are glycosylated (starred protein identified as BMP-3).FIGS. 11-12 show immunodetection of two specific proteins (BMP-7,FIG. 14 and BMP-2,FIG. 15 ) treated with increasing levels of PNGase F (Peptide-N-Glycosidase F). Both BMP-2 and BMP-7 show some degree of glycoslyation in BP, but appear to have some level of protein resistant to PNGase F as well (plus signs indicate increasing levels of enzyme). Functional activity of PNGase F and sialadase treated samples were assayed by explant mass and by ALP score, as shown inFIGS. 13A and 13B , which shows that glycosylation is required for full activity. - In summary,
BMPs - The methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the method and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
- The following examples are intended to be merely illustrative, and do not limit the scope of the claimed invention.
- Quail chorioallantoic membrane (CAM) was in the manner described in “A Novel Assay of Angiogenesis in the Quail Chorioallantoic Membrane: Stimulation by bFGF and Inhibition by Angiostatin According to Fractal Dimension and Grid Intersection,” Parsons-Wingerter P., Dwai B., Yang M C., Elliot K E., Milaninia A., Redlitz A., Clark J. and Sage E. H. Fertilized Japanese quail eggs (Coturnix coturnix japonica) were opened onto Petri dishes on
day 3 post-incubation (FIG. 20A ). After 4 days of culture, a BDAP mixture, diluted in PBS/ovalubumin prewarmed to 37° C., was distributed evenly onto the surface of the CAM. After 24 hours of incubation, the CAM's were fixed, dissected and photographed (FIG. 20B ) at 10× magnification to visualize the arterial vascular tree, including endstage vessels. Digital images of triplicate CAM specimens were acquired at lOx magnification in grayscale, binarized to black-and-white, and skeletonized (FIG. 20C ). The vessel branching pattern was analyzed and quantified by the fractal dimension. - The photographs in
FIG. 21 are representative digital binarized images of CAMs exposed to 10 μg/ml dose of growth factor for 24 hours. Quantitative data corresponding to these images were acquired by analyzing the skeletonized images and determining the fractal dimension of the branched vascular pattern. Data were pooled from two separate experiments consisting of three CAMs per experiment. Exposure to BDAP resulted in 124% greater mean angiogenic stimulation over the basal rate (defined as the change in fractal dimension in untreated controls) versus a 43% increase over basal rate for bFGF-treated CAMs. (p<0.006). - It is hypothesized that this combination of factors acts synergistically to facilitate the proliferation, migration and differentiation processes essential to angiogenesis more effectively than a single factor.
- Preliminary data suggest that other fractions of proteins eluted from bone are also angiogenic. An assay of a second protein mixture, BDAP-2, defined as the fraction eluting at an acetonitrile concentration of from about 37 to about 39.5 percent, membrane was performed on quail chorioallantoic membrane (CAM) using the same protocol as that described above with respect to the BDAP assay. The angiogenic response in the quail CAM assay was 86 percent greater than the basal angiogenic rate after treatment with this alternative protein mix.
- Four adult mongrel dogs of either sex, weighing 21-26 kg, were anesthetized and a left thoracotomy performed through the fifth intercostal space. All visible epicardial collaterals connecting LAD diagonals to circumflex or right coronary arteries were ligated to minimize collateral flow to the LAD territory and an ameroid constrictor was placed on the proximal to the first diagonal branch. After completing the procedure, 0, 10 or 100 μg BDAP was injected in a 0.1 cc volume of povidone (polyvinylpyrrolidone), as polymer microspheres suspended in povidone, or in collagen gel for a total of nine injections. Each series of injections was administered in the ischemic LAD region of the left ventricle, as well as in a non-ischemic LCX region. The chest was closed and the animal was allowed to recover.
- In order to provide an index of cellular proliferation at multiple time points after the initial surgery, bromodeoxyuridine (BrdU, 25 mg/kg, Sigma, St. Louis, Mo.) was administered subcutaneously on
post-operative days - Initial histological data (FIGS. 22A-E) indicate that 10 or 100 micrograms of BDAP suspended in 0.1 cc povidone stimulated blood vessel formation within two weeks post injection. Whereas control sections showed no significant vessel formation and the needle tract was visible, BDAP-treated sections had several newly formed blood vessels, as evidenced by Masson's trichrome staining (
FIG. 22A ). Immunohistochemical staining demonstrated that these vessels are lined with endothelial cells (dark stainFIG. 22B ) and surrounded by a layer of smooth muscle cells (brown stainFIG. 22C ). PCNA- and BrdU-stained sections (FIGS. 22D-E) indicated that these vascular endothelial and smooth muscle cells are actively proliferating. Thus, based on the qualitative results of the canine study, it was concluded that BDAP stimulates formation of new differentiated blood vessels approximately 50 -100 μm in diameter in canine myocardium. (Note, inFIG. 22A -C, 1 cm≈200 μm; in FIGS. 22D-E, 1 cm≈40 μm). - The purpose of this study was to determine the effects of intramyocardial injections of Sulzer's Growth Factor mixture (GFm, also called ProVascTM). in a canine model of chronic myocardial ischemia. 38 dogs underwent ameroid constrictor placement on the proximal LAD and ligation of visible epicardial vessels collateralizing the LAD territory. Three weeks later, during a second surgery, animals had intramyocardial injections of either placebo, GFm at a concentration of 1 mg/ml or GFm at a concentration of 10 mg/ml. Each injection consisted of 0.15 ml, injections were at a spatial density of ˜1/cm2 over the LAD region. Group assignments were random and investigators were blinded to group assignment until after the analysis of all test results. Animal survived for an additional 6 weeks. Assessments of regional blood flow (by color microspheres), angiography and echocardiography (rest and stress) were performed prior to and after treatment. Histology and necropsy were performed after sacrifice. Results of this prospective, blinded, multifaceted assessment of the effects of GFm showed that the agent has a significant effect on vascular growth assessed histologically and by angiographic criteria. There was no significant effect on blood flow during maximal vasodilatory stress, though technical limitations resulted in inclusion of only a small number of studies for the analysis of maximal blood flow. There was a slight reduction in regional wall motion score during maximum dobutamine stress in the high concentration group, though global resting function was not influenced by treatment.
- Colored Microsphere Study
- Dye-Trak® Colored Microspheres (15±0.1 μm diameter, suspension in saline solution, 0.5
% Tween 80 and 0.1% Thimerosal as a bacteriostat; Triton Technology Inc., San Diego, Calif.) provide a non-radioactive method of measuring regional blood flow. These precision, highly uniform spheres are quantified by spectrophotometry and were used to determine coronary blood flow at rest and during maximum adenosine stress. After randomization of colors, resting blood flow was assessed using rapid infusion of a set of microspheres (COLOR - Dobutamine Stress Echocardiography:
- Within the same 20-22 day window, if possible on a different day, resting and stress echocardiography were performed in the conscious state. These were done using protocols to standardize echocardiographic windows and views. Animals were lying in a left lateral position and a peripheral venous line with stop cock and extension line was placed. A constant flow pump (Harvard Apparatus Inc.,
model 22, South Natick, Mass.) was loaded with a 60 ml syringe containing dobutamine in normal saline. The dobutamine infusion solution was prepared immediately prior to the experiment. The body weight multiplied by 0.048 provided the number of milliliters of a 250 mg/ml stock solution that was diluted with normal saline to a total volume of 60 ml. The syringe was connected to the infusion line. Each echocardiogram was performed by one of 3 experienced echocardiographers completely blinded to group assignment. Animal names, ID numbers, time and dobutamine infusion rates were annotated on the video recording of each study. Baseline recordings under resting conditions at 4 different levels (basal, mid-papillary, low-papillary and apical; seeFIG. 7 ) at each dobutamine infusion rate were acquired (HP Sonos 5500®, S4 transducer 2-2.5 MHz, Hewlett Packard, Andover, Mass.) from a parastemal short axis window. - During dobutamine infusion, images of all four levels were recorded on standard VHS tape for off-line analysis. The experiment was terminated one dosing level after reaching a target heart rate greater than 200/min, or when new onset of wall motion abnormality was noted and persisted for longer than 3 minutes combined with a decrease in mean aortic pressure.
- Randomization and Blinding
- After completing these assessments of flow and function ˜3 weeks after the first surgery, animals were randomly assigned to one of the 3 treatment groups: placebo, low concentration GFm or high concentration GFm. By design, the study intended to have a total of 21 animals reach the end of the protocol, 7 in each treatment group, with males and females approximately evenly distributed within each group. 21 envelopes each containing a single treatment group assignment (7 for each group, approximately equally distributed between male and female) were prepared and randomly ordered; each envelope was labeled “male” or “female” so as to guide animal recruitment through the course of the study. On the day prior to the “second surgery” (see next section), an envelope from the stack corresponding to the gender of the animal was randomly chosen from those remaining and was opened by an investigator independent of all other aspects of the investigation. On the day of the second surgery, the assignment group was reviewed by the independent investigator who prepared the treatment solution. All solutions were prepared in a secluded section of the laboratory. All solutions were identical in appearances and were provided to the primary investigators during the surgery approximately 30 minutes before injection. In the event that an animal died at any time before the end of the study or could not complete the study for any reason, the animal was replaced by another animal of the same sex into the same treatment group. As will be detailed, a total of 38 animals were enrolled in order to obtain the 21 survivors who completed the entire study. All animals are accounted for as detailed in Results. All investigators involved in caring for the animals, performing tests, analyzing data or making any interpretations of the test results were completely blinded to group assignment.
- Baseline Coronary Angiography and Second Surgery for Intramyocardial Injections Of Gfm Or Placebo (Second Operation, Op2)
- Approximately 21 days after the first surgery and after completing the baseline microsphere and stress echocardiographic studies (study CEI), each dog was anesthetized using the same anesthetic protocol as for the first surgery. Urine samples were obtained using either a urinary catheter or a suprapubic cannula and these were submitted for routine analysis. If possible, the samples were taken prior to angiography. If the bladder was empty, urine had to be withdrawn after surgery. The right femoral artery was surgically exposed and a standard left coronary artery catheter1 was introduced under fluoroscopic guidance through the artery into the left main coronary artery. Angiography was performed2 using standard views to visualize the left anterior descending artery (LAD) and diagonal vessels. These sequences were recorded on VHS videotape. After completing the angiography, the catheter was withdrawn, the femoral artery ligated, and the skin incision closed.
1Cordis Super Torque Plus™ angiographic catheter, JL3.5 .6F 100 cm, ref cat. no. 533-618, Cordis Corporation, Miami Fla. or Schneider Guider™ Softip® Guiding Catheter, Judkins Left 2.5 “Classic” JL3.56F 100 cm, model number S6-JL3.5FC, Schneider (USA) Inc, Pfizer Medical Technology Group, Minneapolis, Minn. or ACS Viking™ Guiding Catheter, Amplatz LeftAL I 6F 100 cm, Guidant Advanced Cardiovascular Systems, Inc., Temecula, Calif. 2Visipaque® (iodixanol), nonionic, iodinated x-ray contrast agent, Nycomed Inc., Princeton, N.J.
- The chest was then prepared and draped in the usual sterile fashion and the chest opened in the 5th intercostal space. At this time the animal was then treated in a blinded manner according to the randomization assignment described above. Animals in
Group 1 received intramyocardial GFm injections at a GFm concentration of 1 mg/ml, 0.15 ml/injection, 1 injection/cm2 to the LAD region, total of 15-20 injections per heart.Group 2 animals received intramyocardial GFm injections, at a GFm concentration of 10 mg/ml, 0.15 ml/injection, 1 injection/cm2 to the LAD region, total of 15-20 injections per heart.Group 3 animals received intramyocardial injections of vehicle (1% LMW Povidone) without GFm, 0.15 ml/injection, 1 injection/cm2 to the LAD region, total of 15-20 injections per heart. Injection solutions were prepared by two individuals who were independent of the group of investigators performing the surgeries and follow-up tests. A shallow stitch (4-0 Prolene® taper RB-1 monofilament polypropylene suture, Ethicon, Inc., Somerville, N.J.) was placed over each injection site so that each site could be identified when the heart was removed 6 weeks later. After completing the injections, the heart surface was photographed in order to document the injection site placement. After infiltration of the intercostal musculature with 5 ml of Marcaine® (bupivacaine) the chest was closed in layers (umbilical tape, Ethicon Inc. and 2-0 Vicryl™ taper CT-1 polyglactin sutures, Ethicon Inc., Somerville, N.J.), the pneumothorax was reduced and the animal was allowed to recover. - Each dog received subcutaneous injections of 5-Bromo-2′-Deoxyuridine (BrdU, B-5002, Sigma-Aldrich, St. Louis, Mo.; diluted in 0.9% saline solution, adjusted with KOH to pH 9.0) starting the day before surgery (25 mg/kg), on the day of surgery (15 mg/kg) and
days - Physiologic Assessment of Blood Flow and
Myocardial Function 3 Weeks After Treatment (Second Conscious Experiment, Ce2) - Between 20 and 22 days (approximately 3 weeks) after the second surgery, blood flow was assessed in the conscious state only during adenosine stress using the third colored microsphere (COLOR 3). Resting blood flow was not measured because there are only 5 different colored microspheres; 2 colors have been used at baseline and 2 are required at the final time point (CE3, see next section). Within the same 20-22 day time window, the resting echocardiogram was repeated. The same protocols for performing microsphere infusions, reference blood sample withdrawals and echocardiography used during the initial evaluations were employed. Blood samples were also obtained for routine analysis in a conventional manner.
- Physiologic Assessment of Blood Flow and
Myocardial Function 6 Weeks After the Second Surgery (Third Conscious Experiment, Ce3) - Between 40 and 44 days (approximately 6 weeks) after the second surgery, blood flow was assessed at rest and during adenosine stress using the fourth and fifth colored microsphere (
COLOR 4 and COLOR 5). Resting and dobutamine stress echocardiographic tests were also performed. Blood flow and echocardiographic tests were performed a minimum of 4 hours apart from each other, preferably on different days within the 40-44 day time window. The same protocols detailed above for performing microsphere infusions, reference blood sample withdrawals, echocardiograms and dobutamine infusion used during the initial evaluations were employed. Blood samples were also obtained to measure a host of chemical and hematologic parameters. - Coronary Angiography Followed by Sacrifice of the Animal and Procurement of Tissue Samples (Terminal Experiment and Sacrifice, Te/Sac)
- After completing blood flow and myocardial functional assessments with echocardiography, animals were anesthetized as described above, urine samples were collected in the same manner as during the second surgery and angiography was repeated using the left femoral artery to introduce the coronary catheter. Images were recorded on VHS tape for off-line analysis. After completing the angiography, the animal was sacrificed with an overdose of phenobarbital and the heart was removed. Three transmural tissue blocks, each containing 1 or 2 injection sites (identified by the previously placed epicardial stitches) were isolated in individual transmural tissue blocks. These were cut into three approximately equal thickness sections (epicardial, midwall and endocardial) and placed in 10% neutral buffered formalin (buffered Formalde-Freshφ,
low odor 10% Formalin, cat. SF 93-20, Fisher, Fair Lawn, N.J.) for fixation. These sections were taken from the central region of the ischemic territory. The remainder of the heart was cut into approximately 1 gram tissue blocks, with a map of where individual samples were derived (including epicardial and endocardial location; seeFIG. 8 ) and these were submitted together with samples from both kidneys for microsphere analysis. In addition, other organs (lungs, liver, spleen, kidneys, brain, and small intestines) were harvested, weighed and examined grossly and histologically by a certified veterinary pathologist for signs of remote tissue effects of GFm. - After completing the analysis of the study of all results, a table was constructed which summarized the findings of angiography (Angio), histology (Histo), descriptive echocardiographic findings (Echo D), change in echocardiographic wall motion score (Echo WM), change in fractional area shortening from echocardiography (ΔFAC, difference between baseline and final FAC in percentage points) and percent change in blood flow from colored microsphere analysis (CMS, Δ%) were determined. The analysis techniques were as follows:
- Angiography was graded on a 3 point semiquantitative scale: 0, no improvement; 1+ mild improvement in distal LAD visualization; 2+ significant improvement in distal LAD visualization. As summarized in the tables, there was a statistically significant improvement in the angiographic score at both high and low concentrations compared to the placebo group. In addition, there was a nearly statistically significant difference between low and high concentration treatments, suggesting a concentration-dependent improvement in blood flow to the distal LAD.
- In addition to the graded angiography results given in Table 2,
FIGS. 23-26 illustrate the marked improvement in blood flow that resulted from treatment with the inventive composition. InFIGS. 23 and 25 , the angiograms are taken at the beginning of the marking process, while the angiograms ofFIGS. 24 and 26 are taken after a significant of the radio-opaque marker has been injected. In each of angiograms comprisingFIGS. 23, 24 , and 25, the visible portion of the LAD is relatively short, indicating that the radio-opaque marker has not entered the LAD. In marked contrast, the LAD is much more visible inFIG. 26 , indicating that blood is flowing in the region. ComparingFIGS. 24 and 26 , it can be seen that that blood flow past the ameriod constrictor is small inFIG. 24 , even well into the injection, whereas blood flow past the ameroid constrictor (via natural bypass mechanisms, i.e. new vessel growth) is greatly improved followed treatment with the inventive composition, as seen inFIG. 26 . Hence, it is clear that the administration of an angiogenic factor according to the present invention greatly increases the natural bypass of the LAD or other occluded vessel and allows significant blood flow into a previously ischemic region. - The histologic findings from each animal were reviewed globally and were graded semiquantitatively on a 3 point scale: 0, no significant vascular growth detected; 1+ mild-to-moderate degree of vascular growth detected; 2+, significant amount of vascular growth detected. As summarized in the tables, there was a statistically significant, concentration dependent increase the semi-quantitative grading of vascular growth.
- The echocardiograms were analyzed in 3 ways (as summarized in Methods above). EchoD was a semiquantitative descriptive parameter obtained by having an experienced echocardiographer examining changes in the individual wall motion scores between baseline and the final study (CE 3). EchoD was a 3 point scale: −1, worsened wall motion during stress; 0, no change in wall motion during stress; 1+ improved wall motion during stress. This parameter tended to decrease in the high concentration group but this was not statistically significant. EchoWM was the change in the sum of wall motion scores; a lower number for this parameter indicates better function. Similar to the EchoD parameter, there was a slight decrease in function detected in the high concentration group. The third parameter was the change in the percent fractional shortening showed no significant difference between groups.
- Microsphere-derived blood flow measurements from all hearts at all conditions measured are shown in Table 1. Prior to any treatment (CE 1), blood flow at rest was similar in all groups and only mildly decreased from the control area, reaching statistical significance only in the Placebo group. During stress, by definition, blood flow in the ischemic and border zones were decreased compared to the control region. During the second conscious experiments (3 weeks after treatment, CE 2), blood flow during stress had not changed significantly in any group; blood flow in the ischemic area was approximately half that in the control region in all groups.
- Similarly, 6 weeks after treatment blood flow at rest and during stress was similar in all groups and had not changed significantly over time in any group.
TABLE 1 Myocardial Perfusion (ml/min/g tissue)-Results from All animals. (all values are mean ± SEE) Number of animals Placebo 7 Low Conc. GFm 7High Conc. GFm 7CE 1: Rest Ischemia 0.76 ± 0.06* 0.91 ± 0.17 0.90 ± 0.10 Borderzone 0.84 ± 0.11 0.92 ± 0.16 1.04 ± 0.13 Control area 0.94 ± 0.07 0.95 ± 0.15 1.18 ± 0.12 CE 1: Stress Ischemia 1.66 ± 0.18* 1.83 ± 0.19* 1.79 ± 0.15* Border zone 2.55 ± 0.26*# 2.39 ± 0.29*# 2.49 ± 0.17*# Control area 4.07 ± 0.53 3.70 ± 0.37 4.29 ± 0.36 CE 2: Stress Ischemia 1.73 ± 0.26* 2.17 ± 0.19* 1.79 ± 0.14* Border zone 2.98 ± 0.46*# 3.00 ± 0.28*# 2.46 ± 0.38*#=.056 Control 4.41 ± 0.69 4.32 ± 0.35 3.73 ± 0.53 CE 3: Rest Ischemia 0.70 ± 0.05* 1.07 ± 0.25* 0.90 ± 0.12* Border zone 0.85 ± 0.08 1.16 ± 0.25 1.04 ± 0.17 Control area 0.97 ± 0.07 1.30 ± 0.26 1.22 ± 0.16 CE 3: Stress Ischemia 1.90 ± 0.18* 2.21 ± 0.12* 1.93 ± 0.19* Border zone 2.81 ± 0.16*# 3.13 ± 0.16*# 2.73 ± 0.29*# Control area 3.98 ± 0.37 4.51 ± 0.22 4.37 ± 0.43
*p < 0.05 vs. control area,
#p < 0.05 vs. ischemic area.
no significant differences between groups or within groups CE1 vs. CE3.
Statistical comparisons done with one way ANOVA with Scheffe post hoc test
- Lack of uniform maximal vasodilation induced by intravenous adenosine prohibited assessment of blood flow during maximal vasodilatory stress in a large number of animals. As a result, there was a small number values for comparison in each group and there were no statistically significant differences between groups with regard to how blood flow during stress changed in response to treatment.
- After unblinding, the results of these measurements were sorted by group and are tabulated in Table 2.
TABLE 2 Overview of results in each animal sorted by group. Group Name Nr. ID # Angio Histo EchoD EchoWM ΔFAC CMS GFm 1 Leoncavallo 8 3581 1+ 2+ 1+ −2 −15 n/i mg/ml Monteverdi 10 3879 1+ 1+ 1+ −1 17 1 Mozart 11 3605 1+ 1+ 1− 0 −5 −7 Puccini 16 3970 1+ 0/1+2 1+ −5 −4 −1 Rossini 18 11767 1+ 0/1+2 1−4 4 11 n/i Schumann 20 10568 1+ n/a2,3 1+ −3 1 −4 Lautrec 36 12545 2+ 1+ 1+ 4 −10 −1 Mean 1.1 1.0 0.4 −0.4 −4* −2.4 GFm 10 Vivaldi 25 4018 1+ 1+3 1+ −3 5 −2 mg/ml Boticelli 27 11190 2+ 1+ 1− 4 2 1 Dali 29 11187 2+ 2+ 0 2 −10 −7 Degas 30 4070 2+ 2+ 0 −1 −6 n/i Gauguin 32 12311 2+ 2+ 1− 4 −4 n/i Matisse 38 4209 0 2+ 1− 5 3 n/i Michelangelo 39 11745 2+ 2+ 1− 4 −5 6 Mean 1.6 1.7 −0.4 2.1 −4* −0.5 Placebo Dvorak 5 10213 0 0 1+ −4 −3 n/i Gershwin 6 3711 1+ 0/1+1 1+ −4 1 6 Mussorgsky 12 11334 1+ 1+ 1− −1 15 n/i Offenbach 13 3889 1+ 0 1+ −4 0 5 Tchaikovsky 23 4130 0 0 1+ −4 7 n/i Klimt 35 4143 0 0 0 0 54 −14 Lichtenstein 37 4023 0 0 1+ 0 −2 18 Mean 0.4 0.2 0.6 −2.4 1* 3.75
*Median used instead of mean because of large non-normal distribution.
N/i, not included. See
1histology suggestive of presence of myocardial infarction
2technical problem with histologic staining
3histology suggestive of myocardial infarction alone
4The score for this animal was initially inadvertently entered onto the table sent to the Sponsor as “0”; this should have been entered as “1−”, as it now appears
- In summary, the general results of this prospective, blinded, multifaceted assessment of the effects of GFm showed that the agent has a concentration-dependent significant effect on vascular growth assessed histologically and by angiographic criteria. There was no significant effect on blood flow during maximal vasodilatory stress, though technical limitations resulted in inclusion of only a small number of studies for the analysis of maximal blood flow rendering the results inconclusive. There was a trend (not statistically significant) towards a slight reduction in regional wall motion score during maximum dobutimine stress, though global resting function was not influenced by treatment. Nonethless, there is histologic and angiographic evidence of significant vascular growth, though LV function during stress and blood flow by color microsphere analysis did not improve.
- Administration of angiogenic factors in accordance with the present invention has several advantages over the alternative methods for inducing angiogenesis, such as inflammation resulting from laser injury. The growth factors of the present invention can be delivered in a minimally invasive manner to ischemic tissues either through a thoracotomy or percutaneous catheterization without the use of expensive equipment. In addition, the process for manufacturing the present angiogenic factors can be readily scaled up to a commercial production scale. A further advantage is that the proteins are kept in solution during the purification steps and exhibit little deterioration during the production process. Another advantage is that the resultant mixture of proteins can be used directly, without the mixing that may be required with proteins produced by other processes.
- While the present angiogenic factor and methods for producing and administering it have been described according to a preferred embodiment, it will be understood that departures can be made from some aspects of the foregoing description without departing from the scope of the invention.
Claims (8)
1.-30. (canceled)
31. A composition, comprising:
a mixture of proteins derived from ground bone comprising an amount of at least two growth factors selected from the group consisting of bone morphogenic protein-2 (BMP-2), bone morphogenic protein-3 (BMP-3), bone morphogenic protein-4 (BMP-4), bone morphogenic protein-5 (BMP-5), bone morphogenic protein-6 (BMP-6), bone morphogenic protein-7 (BMP-7), transforming growth factor 1 (TGF-β1), transforming growth factor β2 (TGF-β2), transforming growth factor β3 (TGF-β3) and fibroblast growth factor 1 (FGF-1) effective to promote angiogenesis in soft tissue in a mammal.
32. The composition of claim 1, wherein the mixture of proteins further comprises a growth factor selected from the group consisting of insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF), hepatocyte growth factor (HGF), transforming growth factor α (TGF-α), and platelet-derived growth factor (PDGF).
33. The composition of claim 1, further comprising a preservative or an adjuvant.
34. The composition of claim 1, wherein the mixture or proteins comprises BMP-2, BMP-3, BMP-7, TGF-β, and FGF-1.
35. The composition of claim 1, further comprising a carrier selected from the group consisting of polylactic acid, polyglycolic acid, copolymers of lactic acid and glycolic acid, collagen, polyoxyalkylene ether copolymer surfactant, and polyvinylpyrrolidone.
36. The composition of claim 5, wherein the carrier is polyvinylpyrrolidone.
37. The composition of claim 5, wherein the composition contains 10 μg of the mixture of proteins per 0.1 cc of polyvinylpyrrolidone or 100 μg of the mixture of proteins per 0.1 cc of polyvinylpyrrolidone.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/359,102 US20060194729A1 (en) | 1998-10-16 | 2006-02-22 | Method of promoting natural bypass |
US11/843,797 US20080031970A1 (en) | 1998-10-16 | 2007-08-23 | Method of Promoting Natural Bypass |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/173,989 US6211157B1 (en) | 1998-05-01 | 1998-10-16 | Protein mixtures to induce therapeutic angiogenesis |
US09/748,038 US7087577B2 (en) | 1998-10-16 | 2000-12-22 | Method of promoting natural bypass |
US11/359,102 US20060194729A1 (en) | 1998-10-16 | 2006-02-22 | Method of promoting natural bypass |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/748,038 Continuation US7087577B2 (en) | 1998-10-16 | 2000-12-22 | Method of promoting natural bypass |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/843,797 Continuation US20080031970A1 (en) | 1998-10-16 | 2007-08-23 | Method of Promoting Natural Bypass |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060194729A1 true US20060194729A1 (en) | 2006-08-31 |
Family
ID=46277202
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/748,038 Expired - Fee Related US7087577B2 (en) | 1998-10-16 | 2000-12-22 | Method of promoting natural bypass |
US11/359,102 Abandoned US20060194729A1 (en) | 1998-10-16 | 2006-02-22 | Method of promoting natural bypass |
US11/843,797 Abandoned US20080031970A1 (en) | 1998-10-16 | 2007-08-23 | Method of Promoting Natural Bypass |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/748,038 Expired - Fee Related US7087577B2 (en) | 1998-10-16 | 2000-12-22 | Method of promoting natural bypass |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/843,797 Abandoned US20080031970A1 (en) | 1998-10-16 | 2007-08-23 | Method of Promoting Natural Bypass |
Country Status (1)
Country | Link |
---|---|
US (3) | US7087577B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080031970A1 (en) * | 1998-10-16 | 2008-02-07 | Zimmer Orthobiologics, Inc. | Method of Promoting Natural Bypass |
US20080113916A1 (en) * | 1998-10-16 | 2008-05-15 | Zimmer Orthobiologies, Inc. | Povidone-Containing Carriers for Polypeptide Growth Factors |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0896825B1 (en) * | 1997-08-14 | 2002-07-17 | Sulzer Innotec Ag | Composition and device for in vivo cartilage repair comprising nanocapsules with osteoinductive and/or chondroinductive factors |
US6723335B1 (en) * | 2000-04-07 | 2004-04-20 | Jeffrey William Moehlenbruck | Methods and compositions for treating intervertebral disc degeneration |
US7232802B2 (en) * | 2001-12-21 | 2007-06-19 | Zimmer Orthobiologics, Inc. | Compositions and methods for promoting myocardial and peripheral angiogenesis |
US7241874B2 (en) * | 2002-06-26 | 2007-07-10 | Zimmer Ortho Biologics, Inc. | Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue |
US7622562B2 (en) * | 2002-06-26 | 2009-11-24 | Zimmer Orthobiologics, Inc. | Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue |
WO2005033300A1 (en) * | 2003-10-01 | 2005-04-14 | Cedars-Sinai Medical Center | System and method for xenobiotic cell and tissue culture supported by surrogate avian vascular circulation |
US20080159604A1 (en) * | 2005-12-30 | 2008-07-03 | Allan Wang | Method and system for imaging to identify vascularization |
US8933009B2 (en) | 2013-03-12 | 2015-01-13 | Ecolab Usa Inc. | Surfactant blends for cleaning filtration membranes |
JP7074845B2 (en) | 2017-09-29 | 2022-05-24 | エコラボ ユーエスエー インコーポレイティド | Use of extended surfactants in process membrane cleaning |
EP3752278A1 (en) | 2018-02-14 | 2020-12-23 | Ecolab USA Inc. | Compositions and methods for the reduction of biofilm and spores from membranes |
Citations (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4529950A (en) * | 1982-03-02 | 1985-07-16 | Henri Chazenfus | Digital phase and amplitude modulator |
US4699788A (en) * | 1984-08-20 | 1987-10-13 | Trustees Of Boston University | Angiogenic factor methods of extraction and method for producing angiogenesis |
US4863732A (en) * | 1987-12-16 | 1989-09-05 | Collagen Corporation | Injectable composition for inductive bone repair |
US4895838A (en) * | 1988-03-09 | 1990-01-23 | Trustees Of Boston University | Method for provoking angiogenesis by administration of angiogenically active oligosaccharides |
US4900673A (en) * | 1988-03-28 | 1990-02-13 | President And Fellows Of Harvard College | Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression |
US4950483A (en) * | 1988-06-30 | 1990-08-21 | Collagen Corporation | Collagen wound healing matrices and process for their production |
US5116738A (en) * | 1986-07-01 | 1992-05-26 | Genetics Institute, Inc. | DNA sequences encoding |
US5141905A (en) * | 1986-07-01 | 1992-08-25 | Rosen Vicki A | Dna sequences encoding bmp-7 proteins |
US5187076A (en) * | 1986-07-01 | 1993-02-16 | Genetics Institute, Inc. | DNA sequences encoding BMP-6 proteins |
US5219576A (en) * | 1988-06-30 | 1993-06-15 | Collagen Corporation | Collagen wound healing matrices and process for their production |
US5270300A (en) * | 1991-09-06 | 1993-12-14 | Robert Francis Shaw | Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone |
US5290763A (en) * | 1991-04-22 | 1994-03-01 | Intermedics Orthopedics/Denver, Inc. | Osteoinductive protein mixtures and purification processes |
US5318957A (en) * | 1992-09-02 | 1994-06-07 | The United States Of America As Represented By The Department Of Health And Human Services | Method of stimulating angiogenesis |
US5328695A (en) * | 1983-03-22 | 1994-07-12 | Massachusetts Institute Of Technology | Muscle morphogenic protein and use thereof |
US5459047A (en) * | 1986-07-01 | 1995-10-17 | Genetics Institute, Inc. | BMP-6 proteins |
US5470831A (en) * | 1990-12-21 | 1995-11-28 | Curative Technologies, Inc. | Angiogenic peptides |
US5543392A (en) * | 1992-07-29 | 1996-08-06 | Morinaga Milk Industry Co., Ltd. | Digestive tract cell activating agent of EGF and lactoferrin |
US5543394A (en) * | 1986-07-01 | 1996-08-06 | Genetics Institute, Inc. | Bone morphogenetic protein 5(BMP-5) compositions |
US5563124A (en) * | 1991-04-22 | 1996-10-08 | Intermedics Orthopedics/ Denver, Inc. | Osteogenic product and process |
US5595722A (en) * | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
US5616490A (en) * | 1992-12-07 | 1997-04-01 | Ribozyme Pharmaceuticals, Inc. | Ribozymes targeted to TNF-α RNA |
US5631142A (en) * | 1986-07-01 | 1997-05-20 | Genetics Institute, Inc. | Compositions comprising bone morphogenetic protein-2 (BMP-2) |
US5635372A (en) * | 1995-05-18 | 1997-06-03 | Genetics Institute, Inc. | BMP-15 compositions |
US5637480A (en) * | 1993-05-12 | 1997-06-10 | Genetics Institute, Inc. | DNA molecules encoding bone morphogenetic protein-10 |
US5656587A (en) * | 1982-09-24 | 1997-08-12 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Promotion of cell proliferation by use of transforming growth factor beta (TGF-β) |
US5661007A (en) * | 1991-06-25 | 1997-08-26 | Genetics Institute, Inc. | Bone morphogenetic protein-9 compositions |
US5677276A (en) * | 1994-12-23 | 1997-10-14 | La Jolla Cancer Research Foundation | Immobilization of peptides to hyaluronate |
US5705477A (en) * | 1982-09-24 | 1998-01-06 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions of transforming growth factor β(TGF-β) which promotes wound healing and methods for their use |
US5741524A (en) * | 1995-01-09 | 1998-04-21 | Edward Mendell Co., Inc. | Sustained-release formulations utilizing pharmaceutical excipient having improved compressibility |
US5846770A (en) * | 1994-11-22 | 1998-12-08 | Genetics Institute, Inc. | DNA molecules encoding human chordin |
US5854207A (en) * | 1995-12-12 | 1998-12-29 | Stryker Corporation | Compositions and therapeutic methods using morphogenic proteins and stimulatory factors |
US5866364A (en) * | 1991-11-04 | 1999-02-02 | Genetics Institute, Inc. | Recombinant bone morphogenetic protein heterodimers |
US5902785A (en) * | 1995-06-06 | 1999-05-11 | Genetics Institute, Inc. | Cartilage induction by bone morphogenetic proteins |
US5928940A (en) * | 1996-09-24 | 1999-07-27 | Creative Biomolecules, Inc. | Morphogen-responsive signal transducer and methods of use thereof |
US5965403A (en) * | 1996-09-18 | 1999-10-12 | Genetics Institute, Inc. | Nucleic acids encoding bone morphogenic protein-16 (BMP-16) |
US5972884A (en) * | 1991-03-11 | 1999-10-26 | Creative Biomolecules, Inc. | Morphogen treatment of gastrointestinal ulcers |
US5981489A (en) * | 1996-07-18 | 1999-11-09 | Alza Corporation | Non-aqueous protic peptide formulations |
US5994094A (en) * | 1993-08-10 | 1999-11-30 | Biopharm Gesellschaft Zur Biotechnologischen | Growth/differentiation factor of the TGF-β family |
US6051648A (en) * | 1995-12-18 | 2000-04-18 | Cohesion Technologies, Inc. | Crosslinked polymer compositions and methods for their use |
US6120760A (en) * | 1992-02-12 | 2000-09-19 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung | Growth/differentiation factors of the TGF-β family |
US6124273A (en) * | 1995-06-09 | 2000-09-26 | Chitogenics, Inc. | Chitin hydrogels, methods of their production and use |
US6150328A (en) * | 1986-07-01 | 2000-11-21 | Genetics Institute, Inc. | BMP products |
US6177406B1 (en) * | 1986-07-01 | 2001-01-23 | Genetics Institute, Inc. | BMP-3 products |
US6211157B1 (en) * | 1998-05-01 | 2001-04-03 | Sulzer Biologics, Inc. | Protein mixtures to induce therapeutic angiogenesis |
US20020025340A1 (en) * | 2000-08-30 | 2002-02-28 | Dyer Wallace K. | Methods and compositions for tissue augmentation |
US6372257B1 (en) * | 1999-06-29 | 2002-04-16 | J. Alexander Marchosky | Compositions and methods for forming and strengthening bone |
US6468960B1 (en) * | 1999-04-23 | 2002-10-22 | Prolifia, Inc. | Therapeutic compositions and methods for enhancing angiogenesis |
US20020173453A1 (en) * | 2000-12-15 | 2002-11-21 | Rama Akella | Method of treating renal injury |
US6498142B1 (en) * | 1996-05-06 | 2002-12-24 | Curis, Inc. | Morphogen treatment for chronic renal failure |
US20030022828A1 (en) * | 1998-10-16 | 2003-01-30 | Rama Akella | Povidone-containing carriers for polypeptide growth factors |
US20030104977A1 (en) * | 2000-03-31 | 2003-06-05 | Ugo Ripamonti | Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors |
US7081240B1 (en) * | 2000-06-28 | 2006-07-25 | Zimmer Orthobiologics, Inc. | Protein mixtures for wound healing |
US7087577B2 (en) * | 1998-10-16 | 2006-08-08 | Zimmer Orthobiologies, Inc. | Method of promoting natural bypass |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3036614A1 (en) * | 1980-09-29 | 1982-05-13 | Siemens AG, 1000 Berlin und 8000 München | METHOD FOR DETECTING DIGITAL INFORMATION IN DIGITAL INFORMATION TRANSFER, IN PARTICULAR INFORMATION TRANSFER IN MOBILE RADIO COMMUNICATION SYSTEMS |
US4529590A (en) | 1982-12-27 | 1985-07-16 | Leveen Robert F | Production of angiogenetic factor |
US4804744A (en) * | 1984-01-04 | 1989-02-14 | International Genetic Engineering, Inc. | Osteogenic factors |
DE3588058T3 (en) * | 1984-07-16 | 2005-04-07 | Celtrix Pharmaceuticals, Inc., Palo Alto | Cartilage-inducing polypeptide factors from bone |
US4743259A (en) * | 1986-10-29 | 1988-05-10 | The University Of Virginia Alumni Patents Foundation | Use of demineralized bone matrix in the repair of segmental defects |
US4902296A (en) * | 1986-10-29 | 1990-02-20 | The University Of Virginia Alumni Patents Foundation | Use of demineralized bone matrix in the repair of segmental defects |
US4874746A (en) * | 1987-12-22 | 1989-10-17 | Institute Of Molecular Biology, Inc. | Wound headling composition of TGF-alpha and PDGF |
US5256644A (en) * | 1988-05-20 | 1993-10-26 | Institute Of Molecular Biology, Inc. | Wound healing using IGF-II and TGF |
US5936035A (en) | 1988-11-21 | 1999-08-10 | Cohesion Technologies, Inc. | Biocompatible adhesive compositions |
US5073373A (en) * | 1989-09-21 | 1991-12-17 | Osteotech, Inc. | Flowable demineralized bone powder composition and its use in bone repair |
US5290558A (en) * | 1989-09-21 | 1994-03-01 | Osteotech, Inc. | Flowable demineralized bone powder composition and its use in bone repair |
US5236456A (en) * | 1989-11-09 | 1993-08-17 | Osteotech, Inc. | Osteogenic composition and implant containing same |
GB8927546D0 (en) | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
JP3356775B2 (en) * | 1990-11-30 | 2002-12-16 | セルトリックス ファーマシューティカルズ, インコーポレイテッド | Use of osteogenic proteins for bone repair by co-combination with TGF-β |
EP0516901A1 (en) | 1991-06-06 | 1992-12-09 | Richard L. Lindstrom | Method and apparatus of a serumfree medical solution |
DE4121043A1 (en) * | 1991-06-26 | 1993-01-07 | Merck Patent Gmbh | BONE REPLACEMENT MATERIAL WITH FGF |
US5830859A (en) * | 1992-09-17 | 1998-11-03 | Schmidt; Karlheinz | Complex for inducing bone growth in the maxillary sinus |
US5516532A (en) * | 1994-08-05 | 1996-05-14 | Children's Medical Center Corporation | Injectable non-immunogenic cartilage and bone preparation |
US5707962A (en) * | 1994-09-28 | 1998-01-13 | Gensci Regeneration Sciences Inc. | Compositions with enhanced osteogenic potential, method for making the same and therapeutic uses thereof |
US5994292A (en) * | 1995-05-31 | 1999-11-30 | The United States Of America As Represented By The Department Of Health And Human Services | Interferon-inducible protein 10 is a potent inhibitor of angiogenesis |
US7026292B1 (en) * | 1995-12-12 | 2006-04-11 | Stryker Corporation | Compositions and therapeutic methods using morphogenic proteins and stimulatory factors |
US6322786B1 (en) * | 1996-02-15 | 2001-11-27 | Kansas University Medical Center Research Institute, Inc. | Method of producing bone-inducing agent |
US20010007023A1 (en) * | 1997-08-13 | 2001-07-05 | John W. Lough Jr. | Bone morphogenetic protein and fibroblast growth factor compositions and methods for the induction of cardiogenesis |
US6189537B1 (en) * | 1996-09-06 | 2001-02-20 | Lifenet | Process for producing osteoinductive bone, and osteoinductive bone produced thereby |
US6679918B1 (en) * | 1997-02-13 | 2004-01-20 | Centerpulse Biologics Inc. | Implantable putty material |
CN1068793C (en) * | 1997-04-17 | 2001-07-25 | 中国人民解放军第四军医大学全军创伤骨科研究所 | Osteogenesis stimulin injection and its preparing process |
GB9714276D0 (en) | 1997-07-08 | 1997-09-10 | Univ Dundee | Peptides and related compounds |
EP0896825B1 (en) * | 1997-08-14 | 2002-07-17 | Sulzer Innotec Ag | Composition and device for in vivo cartilage repair comprising nanocapsules with osteoinductive and/or chondroinductive factors |
EP1040126A2 (en) | 1997-12-17 | 2000-10-04 | Curis, Inc. | Methods for maintaining or restoring tissue-appropriate phenotype of soft tissue cells |
US20050096274A1 (en) * | 1998-04-07 | 2005-05-05 | Lough John W. | Bone morphogenetic protein and fibroblast growth factor compositions and methods for the induction of cardiogenesis |
US20030166550A1 (en) * | 1999-08-27 | 2003-09-04 | Chiron Corporation | Angiogenically effective unit dose of FGF-2 and method of use |
EP1121141A2 (en) * | 1998-10-13 | 2001-08-08 | Chiron Corporation | Angiogenically effective unit dose of fgf and method of administering |
EP1207900A2 (en) * | 1999-08-13 | 2002-05-29 | Chiron Corporation | Dose of an angiogenic factor and method of administering to improve myocardial blood flow |
US6541447B1 (en) * | 1999-09-01 | 2003-04-01 | B & M Healthcare Technologies, Inc. | Wound healing composition and method for use thereof |
US6534095B1 (en) * | 1999-09-03 | 2003-03-18 | Lifenet | Pulsatile acidification wave demineralization process for producing osteoinductive bone; and osteoinductive bone produced thereby |
US20010041792A1 (en) * | 2000-02-03 | 2001-11-15 | Donda Russell S. | Extraction of growth factors from tissue |
US7105168B1 (en) * | 2002-06-04 | 2006-09-12 | D. Collen Research Foundation Vzw | Method of improving ischemic muscle function by administering placental growth factor |
US6930089B2 (en) * | 2000-02-04 | 2005-08-16 | D. Collen Research Foundation Vzw | Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic disease or stroke |
US7166280B2 (en) * | 2000-04-06 | 2007-01-23 | Franco Wayne P | Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease |
US20050064041A1 (en) * | 2000-09-05 | 2005-03-24 | Lifenet | Continuous acidification demineralization process for producing osteoinductive bone; and osteoinductive bone produced thereby |
US6492327B2 (en) * | 2000-12-19 | 2002-12-10 | Sulzer Biologics Inc. | Isolation of purified TGF- β1 and TGF -β2 from bone tissue |
US7241446B2 (en) * | 2002-04-01 | 2007-07-10 | Trustees Of Dartmouth College | Methods for modulating angiogenesis via VEGF |
US7241874B2 (en) * | 2002-06-26 | 2007-07-10 | Zimmer Ortho Biologics, Inc. | Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue |
US20070066525A1 (en) * | 2004-02-04 | 2007-03-22 | Lee John C | Compositions and therapeutic methods using morphogenic proteins |
US20060057184A1 (en) * | 2004-09-16 | 2006-03-16 | Nycz Jeffrey H | Process to treat avascular necrosis (AVN) with osteoinductive materials |
US8568761B2 (en) * | 2005-07-15 | 2013-10-29 | Cormatrix Cardiovascular, Inc. | Compositions for regenerating defective or absent myocardium |
US20070014869A1 (en) * | 2005-07-15 | 2007-01-18 | Cormatrix Cardiovascular, Inc. | Compositions for reconstruction, replacement or repair of intracardiac tissue |
-
2000
- 2000-12-22 US US09/748,038 patent/US7087577B2/en not_active Expired - Fee Related
-
2006
- 2006-02-22 US US11/359,102 patent/US20060194729A1/en not_active Abandoned
-
2007
- 2007-08-23 US US11/843,797 patent/US20080031970A1/en not_active Abandoned
Patent Citations (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4529950A (en) * | 1982-03-02 | 1985-07-16 | Henri Chazenfus | Digital phase and amplitude modulator |
US5705477A (en) * | 1982-09-24 | 1998-01-06 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions of transforming growth factor β(TGF-β) which promotes wound healing and methods for their use |
US5656587A (en) * | 1982-09-24 | 1997-08-12 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Promotion of cell proliferation by use of transforming growth factor beta (TGF-β) |
US5328695A (en) * | 1983-03-22 | 1994-07-12 | Massachusetts Institute Of Technology | Muscle morphogenic protein and use thereof |
US4699788A (en) * | 1984-08-20 | 1987-10-13 | Trustees Of Boston University | Angiogenic factor methods of extraction and method for producing angiogenesis |
US6177406B1 (en) * | 1986-07-01 | 2001-01-23 | Genetics Institute, Inc. | BMP-3 products |
US6150328A (en) * | 1986-07-01 | 2000-11-21 | Genetics Institute, Inc. | BMP products |
US5141905A (en) * | 1986-07-01 | 1992-08-25 | Rosen Vicki A | Dna sequences encoding bmp-7 proteins |
US5187076A (en) * | 1986-07-01 | 1993-02-16 | Genetics Institute, Inc. | DNA sequences encoding BMP-6 proteins |
US5849880A (en) * | 1986-07-01 | 1998-12-15 | Genetics Institute, Inc. | Bone morphogenetic protein (BMP)--6 |
US5116738A (en) * | 1986-07-01 | 1992-05-26 | Genetics Institute, Inc. | DNA sequences encoding |
US5631142A (en) * | 1986-07-01 | 1997-05-20 | Genetics Institute, Inc. | Compositions comprising bone morphogenetic protein-2 (BMP-2) |
US5459047A (en) * | 1986-07-01 | 1995-10-17 | Genetics Institute, Inc. | BMP-6 proteins |
US5543394A (en) * | 1986-07-01 | 1996-08-06 | Genetics Institute, Inc. | Bone morphogenetic protein 5(BMP-5) compositions |
US4863732A (en) * | 1987-12-16 | 1989-09-05 | Collagen Corporation | Injectable composition for inductive bone repair |
US4895838A (en) * | 1988-03-09 | 1990-01-23 | Trustees Of Boston University | Method for provoking angiogenesis by administration of angiogenically active oligosaccharides |
US4900673A (en) * | 1988-03-28 | 1990-02-13 | President And Fellows Of Harvard College | Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression |
US5219576A (en) * | 1988-06-30 | 1993-06-15 | Collagen Corporation | Collagen wound healing matrices and process for their production |
US4950483A (en) * | 1988-06-30 | 1990-08-21 | Collagen Corporation | Collagen wound healing matrices and process for their production |
US5470831A (en) * | 1990-12-21 | 1995-11-28 | Curative Technologies, Inc. | Angiogenic peptides |
US5972884A (en) * | 1991-03-11 | 1999-10-26 | Creative Biomolecules, Inc. | Morphogen treatment of gastrointestinal ulcers |
US5563124A (en) * | 1991-04-22 | 1996-10-08 | Intermedics Orthopedics/ Denver, Inc. | Osteogenic product and process |
US5371191A (en) * | 1991-04-22 | 1994-12-06 | Poser; James W. | Osteoinductive protein mixtures and purification processes |
US5290763A (en) * | 1991-04-22 | 1994-03-01 | Intermedics Orthopedics/Denver, Inc. | Osteoinductive protein mixtures and purification processes |
US5661007A (en) * | 1991-06-25 | 1997-08-26 | Genetics Institute, Inc. | Bone morphogenetic protein-9 compositions |
US5270300A (en) * | 1991-09-06 | 1993-12-14 | Robert Francis Shaw | Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone |
US5866364A (en) * | 1991-11-04 | 1999-02-02 | Genetics Institute, Inc. | Recombinant bone morphogenetic protein heterodimers |
US6120760A (en) * | 1992-02-12 | 2000-09-19 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung | Growth/differentiation factors of the TGF-β family |
US6197550B1 (en) * | 1992-02-12 | 2001-03-06 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharamaka Mbh | DNA sequences encoding growth/differentiation |
US5543392A (en) * | 1992-07-29 | 1996-08-06 | Morinaga Milk Industry Co., Ltd. | Digestive tract cell activating agent of EGF and lactoferrin |
US5318957A (en) * | 1992-09-02 | 1994-06-07 | The United States Of America As Represented By The Department Of Health And Human Services | Method of stimulating angiogenesis |
US5616490A (en) * | 1992-12-07 | 1997-04-01 | Ribozyme Pharmaceuticals, Inc. | Ribozymes targeted to TNF-α RNA |
US5595722A (en) * | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
US5637480A (en) * | 1993-05-12 | 1997-06-10 | Genetics Institute, Inc. | DNA molecules encoding bone morphogenetic protein-10 |
US5703043A (en) * | 1993-05-12 | 1997-12-30 | Genetics Institute, Inc. | Bone morphogenetic protein-10 (BMP-10) compositions |
US5932216A (en) * | 1993-05-12 | 1999-08-03 | Celeste; Anthony J. | Antibodies to bone morphogenetic protein-10 (BMP-10) |
US5994094A (en) * | 1993-08-10 | 1999-11-30 | Biopharm Gesellschaft Zur Biotechnologischen | Growth/differentiation factor of the TGF-β family |
US5846770A (en) * | 1994-11-22 | 1998-12-08 | Genetics Institute, Inc. | DNA molecules encoding human chordin |
US5677276A (en) * | 1994-12-23 | 1997-10-14 | La Jolla Cancer Research Foundation | Immobilization of peptides to hyaluronate |
US5741524A (en) * | 1995-01-09 | 1998-04-21 | Edward Mendell Co., Inc. | Sustained-release formulations utilizing pharmaceutical excipient having improved compressibility |
US5728679A (en) * | 1995-05-18 | 1998-03-17 | Genetics Institute, Inc. | BMP-15 compositions |
US5635372A (en) * | 1995-05-18 | 1997-06-03 | Genetics Institute, Inc. | BMP-15 compositions |
US5902785A (en) * | 1995-06-06 | 1999-05-11 | Genetics Institute, Inc. | Cartilage induction by bone morphogenetic proteins |
US6124273A (en) * | 1995-06-09 | 2000-09-26 | Chitogenics, Inc. | Chitin hydrogels, methods of their production and use |
US5854207A (en) * | 1995-12-12 | 1998-12-29 | Stryker Corporation | Compositions and therapeutic methods using morphogenic proteins and stimulatory factors |
US6051648A (en) * | 1995-12-18 | 2000-04-18 | Cohesion Technologies, Inc. | Crosslinked polymer compositions and methods for their use |
US6498142B1 (en) * | 1996-05-06 | 2002-12-24 | Curis, Inc. | Morphogen treatment for chronic renal failure |
US5981489A (en) * | 1996-07-18 | 1999-11-09 | Alza Corporation | Non-aqueous protic peptide formulations |
US5965403A (en) * | 1996-09-18 | 1999-10-12 | Genetics Institute, Inc. | Nucleic acids encoding bone morphogenic protein-16 (BMP-16) |
US5928940A (en) * | 1996-09-24 | 1999-07-27 | Creative Biomolecules, Inc. | Morphogen-responsive signal transducer and methods of use thereof |
US6211157B1 (en) * | 1998-05-01 | 2001-04-03 | Sulzer Biologics, Inc. | Protein mixtures to induce therapeutic angiogenesis |
US20030022828A1 (en) * | 1998-10-16 | 2003-01-30 | Rama Akella | Povidone-containing carriers for polypeptide growth factors |
US6992066B2 (en) * | 1998-10-16 | 2006-01-31 | Zimmer Orthobiologics, Inc. | Povidone-containing carriers for polypeptide growth factors |
US7087577B2 (en) * | 1998-10-16 | 2006-08-08 | Zimmer Orthobiologies, Inc. | Method of promoting natural bypass |
US6468960B1 (en) * | 1999-04-23 | 2002-10-22 | Prolifia, Inc. | Therapeutic compositions and methods for enhancing angiogenesis |
US6372257B1 (en) * | 1999-06-29 | 2002-04-16 | J. Alexander Marchosky | Compositions and methods for forming and strengthening bone |
US20030104977A1 (en) * | 2000-03-31 | 2003-06-05 | Ugo Ripamonti | Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors |
US7081240B1 (en) * | 2000-06-28 | 2006-07-25 | Zimmer Orthobiologics, Inc. | Protein mixtures for wound healing |
US20020025340A1 (en) * | 2000-08-30 | 2002-02-28 | Dyer Wallace K. | Methods and compositions for tissue augmentation |
US20020173453A1 (en) * | 2000-12-15 | 2002-11-21 | Rama Akella | Method of treating renal injury |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080031970A1 (en) * | 1998-10-16 | 2008-02-07 | Zimmer Orthobiologics, Inc. | Method of Promoting Natural Bypass |
US20080113916A1 (en) * | 1998-10-16 | 2008-05-15 | Zimmer Orthobiologies, Inc. | Povidone-Containing Carriers for Polypeptide Growth Factors |
Also Published As
Publication number | Publication date |
---|---|
US20080031970A1 (en) | 2008-02-07 |
US7087577B2 (en) | 2006-08-08 |
US20020040004A1 (en) | 2002-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060194729A1 (en) | Method of promoting natural bypass | |
DE60132343T2 (en) | FGF-2 FOR THE TREATMENT OF DISEASES OF PERIPHERAL ARTERIES | |
DE69333040T2 (en) | MORPHOGEN INDUCED NERVES RESTORATION AND RECONSTRUCTION. | |
Walicke | Novel neurotrophic factors, receptors, and oncogenes | |
DE69723429T2 (en) | METHOD FOR IMPROVED FUNCTIONAL RECOVERY OF MOTOR COORDINATION, LANGUAGE OR SENSUAL ASSESSMENT AFTER TRAUMA OR ISCHEMIA OF THE CNS | |
US7579322B2 (en) | Compositions and methods for promoting myocardial and peripheral angiogenesis | |
US6949505B1 (en) | Morphogen-induced dendritic growth | |
AU693489B2 (en) | Method of treating neurological disorders | |
US7081240B1 (en) | Protein mixtures for wound healing | |
DE69915310T2 (en) | METHODS FOR THE TREATMENT OF SALT-RELATED HYPERTENSION | |
EP0534310A1 (en) | Combination containing growth factors and polyelectrolytes | |
US6211157B1 (en) | Protein mixtures to induce therapeutic angiogenesis | |
DE69826854T2 (en) | THERAPIES FOR THE TREATMENT OF ACUTE KIDNEY FAILURES | |
KR20060052692A (en) | Plasmid encoding fibroblast growth factor for the treatment of hypercholesterolemia or diabetes associated angiogenic defects | |
US20060148691A1 (en) | Sustained release preparation for therapy of coronary stenosis or obstruction | |
DE69836830T2 (en) | USE OF PROTEINS FROM THE MIDKINE FAMILY IN THE TREATMENT OF ISCHEMIC ILLNESSES | |
Roethy et al. | A growth factor mixture that significantly enhances angiogenesis in vivo | |
US6732738B1 (en) | Method to enhance healing of sternum after sternotomy | |
DE60110247T2 (en) | Angiogenic tri- or tetrapeptides derived from AcSDKP | |
US8106009B2 (en) | Pharmaceutical composition for preventing or treating ischemic diseases | |
JPH07233085A (en) | Agent for reparation and treatment of cartilage tissue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |